Podcasts about BCD

If you've been gaslit, manipulated, betrayed, ghosted, or are feeling emotionally distressed in a relationship, this episode is for you. Therapist Shannon Petrovich, LCSW, LISAC, BCD—who brings over 30 years of clinical experience—joins host Gretta to explore narcissistic and other toxic relationship dynamics. Together, they offer tools to help you set boundaries, release emotional pain, reclaim your strength, and start your healing journey.In this episode, you'll learn how to:Tell the difference between overt and covert narcissistsSpot trauma bonds and manipulation tacticsUnderstand why someone would ghost you without blocking youOutsmart a narcissist without losing your peaceReframe emotional triggers as healing guidesShannon also shares grounded insights on emotional detachment, self-care, and practical ways to protect yourself from toxic patterns so that you can move forward with clarity and confidence.Shannon Petrovich, LCSW, LISAC, BCD, is a therapist in private practice with over 30 years of experience. Through her book, coaching, and YouTube channel, Shannon helps women heal from narcissistic and other toxic relationships so they can release the hurt and pain, regain their strength and clarity, help their children heal, and choose a better partner in the future.Connect With GrettaFree & Private Facebook Support Group | Instagram | YouTube | copingwithghosting.comHost Gretta Perlmutter, MA, a Certified Post Betrayal Transformation® Coach, delivers evidence-based strategies for turning personal betrayal into a powerful catalyst for growth and healing.Connect with ShannonOut of the FOG, into the CLEAR; Journaling to Help You Heal from Toxic Relationships | Therapist Talks; Thrive Beyond Narcissism YouTube | Shannon's WebsiteMusic: "Ghosted" by Gustavo RamosDisclaimer: This information is designed to mentor and guide you to cope with Ghosting by cultivating a positive mindset and implementing self-care practices. It is for educational purposes only; it solely provides self-help tools. Coping With Ghosting does not provide health care or psychological therapy services and does not diagnose or treat any physical or mental ailment of the mind or body. The content is not a substitute for therapy or any advice given by a licensed psychologist or other licensed or registered professionals.Ghosted? You deserve peace of mind. Explore coaching with Gretta today.Support the showNote to All Listeners: Ghosting is defined as: The practice of ending a personal relationship with someone by suddenly and without explanation withdrawing from all communication (Oxford Languages). When you leave an abusive situation without saying "goodbye," it's not ghosting, it's "self-protection." When you quietly exit a relationship after a boundary has been violated, it's not ghosting, it's "self-respect."

受訪者： 臺北地檢署 高永珍檢察事務官 節目內容： 什麼是刑事被告的具保、責付？限制住居？如何辦理刑事被告的具保？保證金在什麼情況下會被沒入？刑事保證金什麼時候可以請求發還？刑事案件之告訴人或被害人不服法院之判決，應如何提起上訴？對法院的刑事判決不服時，如何尋求救濟？若遭以證人身分傳喚，證人可否不到庭？這些刑事訴訟程序中常會遇到的問題，我們今日就來探討說明如下。 什麼是羈押的替代手段？ 羈押的目的是保證刑事追訴、審判、執行程序不會被干擾，具體方式則是透過拘禁被告來避免其逃亡、湮滅證據。但被告畢竟尚未受到有罪的確定判決，而羈押已經嚴重侵害了被告的人身自由，因此如果「具保」、「責付」及「限制住居」等羈押的替代手段可以達到避免被告逃亡、滅證的羈押目的時，就會依上開方式來取代羈押被告。 什麼是具保？ 具保是指法官或檢察官訊問被告後，在無羈押必要的前提下，命被告提出一筆擔保金，並透過該筆金額來保證被告不會逃亡，也就是俗稱的「交保」。至於說如果具保後被告卻逃亡、隱匿而不出庭，法院可依刑事訴訟法第118條第1項規定，將被告的保釋金沒入，而保釋金的高低，則是由法院依個案來決定。 什麼是責付？ 法院指定某個適當的人選或機關（通常是家人、律師）看管被告，並督促、確保被告受法院傳喚時會準時出庭。被告經准予具保或責付者，由書記官當庭交付「保證書」或「責付證書」或由被告之親友逕向法警室洽辦。 其中的責付，保證書以該管區域內殷實之人所具者為限，並應記載保證金額及依法繳納之事由。並辦理下列手續： A填寫保證書。 B簽名、蓋章或按指印。 C繳驗國民身分證。 D提出財產證明文件。 被告或具保人可依指定之保證金額繳納現金或有價證券免具保證書。

Your rental properties are about to make even more money. There's one often overlooked real estate investing “upside” that, over time, makes rental property investors and landlords rich without any extra effort. This is one upside that Dave is exceptionally bullish on and is one of the most compelling cases for rental property investing. It's not home price growth, it's not tax benefits, and it's not zoning changes—it's simple: rent price growth. Rent has steadily grown throughout the history of the housing market and shot up at an extreme pace during 2020 - 2022. Now, the pendulum is swinging in the other direction as rents soften and tons of supply hit the market. But how far are we from going back to the days of solid rent growth? And with the new housing supply already starting to be absorbed, could we get to above-average rent growth again? We brought Chris Salviati from Apartment List on the show to share his team's rent research.  Over time, your rental income will rise significantly while your mortgage payment stays the same, boosting your profits. So, where are rents poised to grow the most? Will we ever experience 2021-level rent growth again? And will 2025 be the year strong nationwide rent growth returns? We're breaking it all down today so you know exactly where rents are headed next! In This Episode We Cover: Why “rent growth” is one of the most underrated “upsides” of real estate investing The 2020-2022 rent price explosion explained and why rents skyrocketed  What has been keeping rent growth suppressed for the past few years  Markets with rent declines that could quickly reverse (significant buying opportunities) The property classes (A/B/C/D) experiencing the most rental demand (it's NOT the nicest ones!) Multifamily vs. single-family rent trends and whether new apartments drive down home rent prices  And So Much More! Links from the Show Join BiggerPockets for FREE Let Us Know What You Thought of the Show! Ask Your Question on the BiggerPockets Forums BiggerPockets YouTube Apply to Be a BiggerPockets Podcast Guest! Apartment List Research Join the Future of Real Estate Investing with Fundrise Grab Dave's Book, “Real Estate by the Numbers” Sign Up for the BiggerPocket Real Estate Newsletter Find an Investor-Friendly Agent in Your Area Rent Prices Are “Guaranteed” to Increase Over the Next Two Years—Here's Why Grab The Apartment List Research Or Email research@apartmentlist.com Connect with Dave   Check out more resources from this show on BiggerPockets.com and https://www.biggerpockets.com/blog/real-estate-1092 Interested in learning more about today's sponsors or becoming a BiggerPockets partner yourself? Email advertise@biggerpockets.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Slow Chinese Listening Practice HSK4 Standard Course Lesson 5 Listening Q10男：妈，我刚在网上买了台洗衣机，明天上午送到，您明天注意接一下电话。 女：好的。钱交了吗？ 问：洗衣机哪天能送到？BA 17号   B第二天   C下周五  D生日那天

Introducing The Friday Quickie - a triple dose of swoon-worthy romance books, films and TV shows that have JUST dropped (all in less than 15 minutes!) Set in Italy and featuring Felicity's own Scott Foley (hello daddy), this week we've got La Dolce Villa (netflix rarely disappoint when it comes to B/C/D grade rom coms). Feel like cozying up with a book? Say hello to The Deep End by Ali Hazelwood—where love and sex collide with...college watersports. And because we’re not afraid of a little emotional rollercoaster, we finish with We Live in Time. Sob. Buckle up, because we’re about to make your weekend extra romantic. This week's episode is hosted by Ash London and Clara Craig. Love you, more than a friend x

Does when, where, and how the work gets done matter if deadlines and deliverables are met? How do ways of working impact organizations, employees, and travelers? Listen to this podcast to hear our expert panel as they debate the workplace of the future and the role of the travel manager in supporting this transformation. Drawing on the insights from 300+ participants captured at the GBTA Europe Conference and GBTA APAC conferences on varied questions pertaining to work culture, the role of business travel, and travel managers in supporting these new work environments.   Moderator & Speakers: Moderator: Catherine Logan, Regional Senior Vice President - EMEA & APAC – GBTA Christian Dahl, EVP People & Culture at BCD and Rosemary Maloney, Senior Director, Corporate Travel Freeman   Music track is Space Jazz by Kevin MacLeod  Licensed under Creative Commons: By Attribution 3.0 License 

In this special episode of Diabetes Core Update, our host, Dr. Neil Skolnik, discusses with two expert guests the recommendations for respiratory vaccinations in people with diabetes, the rise in vaccine hesitancy and some of the possible reasons for this hesitancy, and several ways to address vaccine hesitancy in the office. This special edition is sponsored by Sanofi.  Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington–Jefferson Health John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair, Department of Family Medicine, Abington–Jefferson Health Aaron Sutton, LCSW, BCD, CAADC, Behavioral Health Faculty at the Family Medicine Residency Program at Abington–Jefferson Health; Chief Wellness Officer for Graduate Medical Education at Abington–Jefferson Health Select references mentioned in the podcast: Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024–25 Influenza Season. MMWR Recomm Rep 2024;73:1–25. DOI: 10.15585/mmwr.rr7305a1 Recombinant or Standard-Dose Influenza Vaccine in Adults Under 65 Years of Age. N Engl J Med 2023;389:2245–2255. DOI: 10.1056/NEJMoa2302099 Influenza Vaccine as a Coronary Intervention for Prevention of Myocardial Infarction. Heart 2016;102:1953–1956. DOI: 10.1136/heartjnl-2016-309983

Let's Get Mental About Healthcare: Episode 158In today's episode, we dive into the male mindset, focusing on the unique challenges men—particularly Black men face in today's world. Joining me are two incredible guests who bring their expertise and personal experiences to the conversation. Phillip J. Lewis, BCD, JD, LICSW, a mental health expert and clinical social therapist. Phillip will share strategies for managing mental health and navigating life's challenges.Neyeswah Abiku, a music teacher and advocate for therapy, who will open up about his own mental health journey and the importance of seeking support.For more information about Phillip J. Lewis and his practice, Lewis & Associates, contact him at 202-240-2870.

Welcome to Your Partner In Success Radio with your Host Denise Griffitts. Our topic today is Unlocking Brain Potential: Brain-centric Design for Strategic Communication with my guest  Rich Carr who is a pioneering Learning Scientist and CEO of Brain-centric, a company that leverages neuroscience to transform communication and education through Brain-centric Design (BcD). This innovative approach reveals how the human brain naturally learns and processes information, empowering professionals across industries to communicate with clarity and impact. Carr's distinguished career includes ownership of radio stations, digital media direction, and consulting for Fortune 100 companies, where his methods have achieved remarkable results, including saving a Fortune 500 company $5.9 million from a single BcD course. He is the co-author of "Brain-centric Design: The Surprising Neuroscience Behind Learning" and author of "SURPRISED: The Science & Art of Engagement." Both of these books are on my desk and next week Rich will join me again to talk about Surprised!An Army veteran and graduate of the Department of Defense Information School, his mission is to align communication strategies with the brain's natural learning processes, helping educators, coaches, and communicators unlock their full potential.Connect with Rich Carr on his website. We appreciate you tuning in to this episode of Your Partner In Success Radio with Host Denise Griffitts. If you enjoyed what you heard, please consider subscribing, rating, and leaving a review on your favorite podcast platform. Your support helps us reach more listeners and create even better content!Stay ConnectedWebsite: Your Partner In Success RadioEmail: mail@yourofficeontheweb.com

A + B + C + D = the good life, as God defines it Letter A -- God's truth: Jesus is Lord! God's grace works powerfully to ignite amazing generosity! Letter B -- God's purpose: Shalom: flourishing for all Letter C -- God's promise: Abundance Letter D -- our God-given identity: We are stewards of God's resources We are beloved children of God

Ми живемо в нестерильному світі. А тому небезпека заразитись гепатитом С, зрештою, як і В, туберкульозом та Віл, стосується кожного. Що треба знати здоровим та інфікованим, аби мінімалізувати ризики,- про це наступний епізод подкасту «Трохи Мович». Його автор Сергій Трухімович зібрав в студії фахівців - Галину Бойчук, лікарку-інфекціоністку І міської поліклініки Львова, Юрія Войналовича, керівника ГО “BCD” та Андрія Орфіна, координатора лікування ВГС у Львівському регіоні, щоб донести загалу експертну думку: ✅ Гепатит С стосується кожного, бо хвороба має безсимптомний перебіг, а ризики заразитися високі: у стоматолога, в тату і манікюрних салонах тощо; ✅ Рекомендації здоровим людям, як вберегтися від зараження гепатитом С; ✅ Покроковий алгоритм для тих, у кого виявлено гепатит С: аналізи, безоплатна державна програма тощо.

Ми живемо в нестерильному світі. А тому небезпека заразитись гепатитом С, зрештою, як і В, туберкульозом та Віл, стосується кожного. Що треба знати здоровим та інфікованим, аби мінімалізувати ризики,- про це наступний епізод подкасту «Трохи Мович». Його автор Сергій Трухімович зібрав в студії фахівців - Галину Бойчук, лікарку-інфекціоністку І міської поліклініки Львова, Юрія Войналовича, керівника ГО “BCD” та Андрія Орфіна, координатора лікування ВГС у Львівському регіоні, щоб донести загалу експертну думку: ✅ Гепатит С стосується кожного, бо хвороба має безсимптомний перебіг, а ризики заразитися високі: у стоматолога, в тату і манікюрних салонах тощо; ✅ Рекомендації здоровим людям, як вберегтися від зараження гепатитом С; ✅ Покроковий алгоритм для тих, у кого виявлено гепатит С: аналізи, безоплатна державна програма тощо.

Hey there, Cassettes! August is here, which can only mean one thing: more episodes of the BCD!! This week, we decided to take a look at one of the most famous comedy teams in history: The Three Stooges.  We returned to our roots this week by having on a guest that hasn't been on our show since season 1: Robin's dad (Bob)! He was kind enough to share his love of the stooges with us, so please join us!

Guang Qu, Co-Founder of NGGT Corporation is focused on developing gene therapy products using dual functional vector strategies. Guang highlights the importance of distinguishing between recessive and dominant mutations in rare diseases and explains how their approach differs from other gene therapy approaches. The two leading indications caused by a gene mutation that NGGT is working on are Bietti's Crystalline Dystrophy (BCD), a rare ocular disease, and phenylketonuria (PKU), a metabolic disease.   Guang explains, "For our strategies and our product development strategies, I think we are leveraging our experience in the gene therapy field. Later, I will talk more about myself, Dr. Lixin Jiang, and our team. The other thing we are leveraging is our fully integrated team in gene therapy product development, which involves R&D, research and development, CGMP manufacturers, from tox development and clinical regulatory functions and the medical teams. So with all of the teams we built up in the last couple of years, we're in very good positions in developing our gene therapy products." "So, of the two currently leading indications, one is involved in ocular disease, what we call the BCD, Bietti's Crystalline Dystrophy. This disease is caused by a gene mutation. The gene mutation causes lipid metabolic problems. The particular gene is called the CYP4V2 gene. The mutation directly leads to the lipid metabolic process being interrupted. Therefore, lipids are precipitated in the different ocular cells, such as the cornea and the retina. That's most of the disease cell layers affected."  #AAV #GeneEditing #GeneTherapy #PKU #BCD Download the transcript here

Guang Qu, Co-Founder of NGGT Corporation is focused on developing gene therapy products using dual functional vector strategies. Guang highlights the importance of distinguishing between recessive and dominant mutations in rare diseases and explains how their approach differs from other gene therapy approaches. The two leading indications caused by a gene mutation that NGGT is working on are Bietti's Crystalline Dystrophy (BCD), a rare ocular disease, and phenylketonuria (PKU), a metabolic disease.   Guang explains, "For our strategies and our product development strategies, I think we are leveraging our experience in the gene therapy field. Later, I will talk more about myself, Dr. Lixin Jiang, and our team. The other thing we are leveraging is our fully integrated team in gene therapy product development, which involves R&D, research and development, CGMP manufacturers, from tox development and clinical regulatory functions and the medical teams. So with all of the teams we built up in the last couple of years, we're in very good positions in developing our gene therapy products." "So, of the two currently leading indications, one is involved in ocular disease, what we call the BCD, Bietti's Crystalline Dystrophy. This disease is caused by a gene mutation. The gene mutation causes lipid metabolic problems. The particular gene is called the CYP4V2 gene. The mutation directly leads to the lipid metabolic process being interrupted. Therefore, lipids are precipitated in the different ocular cells, such as the cornea and the retina. That's most of the disease cell layers affected."  #AAV #GeneEditing #GeneTherapy #PKU #BCD Listen to the podcast here

Research shows ( Darkness to Light White Paper on Prevalence) that one in seven girls and one in 25 boys will be sexually abused before they turn 18. Many by people they know, love and trust. Evidence of abuse is not always obvious and children and adolescents do not report they have been abused for many reasons. Today we are going to lift the silence on childhood sexual abuse to offer an understanding and response to its impact. Toward this goal we are so fortunate to be joined by RICHARD BECK, LCSW, BCD, CGP, FAGPA an experienced psychotherapist with expertise in treating trauma working with individuals, couples and groups. Richard has not only responded to cases of sexual abuse, as a Senior Lecturer at the Columbia University School of Social Work has taught “ Treatment of Childhood Sexual Abuse” over twenty-four times. In our discussion today, Richard Beck will be addressing the reasons victims most often don't report the abuse, the consequences of the Childhood Sexual Abuse on children and adolescents, the signs that might alert caregivers that abuse may have occurred and the rupture of trust and self-blame when a child or teen is victimized by a coach, physician or priest revered by the family.

This episode is for you if you are suffering (in silence or if you feel everyday is a battle for your self worth), in a relationship gone bad or has been bad for years.Shannon Petrovich, LSCW, LISAC, BCD is an expert in the complex world of toxic relationships.This is an especially important interview in light of the many studies highlighting how common it is for women to be the victims of verbal abuse, diminishment, and feelings of shame due to a toxic relationship. This can be from a partner, family member, or even an adult child.According to the American Psychological Association, "One nationally representative study showed that 27% of Americans are actively estranged from at least one family member."Truth is, people who find themselves in this place have often created the very situation they hate. You remember the saying, "we teach people how to treat us?"Yeah, that applies here.But it's not hopeless. You can regain your sense of self worth and teach your people that who you are is not a doormat or victim. Some will respond positively and some will have to be walked away from.Shannon's goal is to help individuals identify toxicity in their relationships and what steps one can take to address these unhealthy dynamics.Shannon helped me understand that narcissism isn't one type of individual or behavior but is rather a spectrum of people and behaviors. Bottom line is this is a tricky situation to navigate due to the chameleon-like nature of a narcissists actions. Key Points Discussed:Personal Experience with Illness: The host shares her recent recovery from illness.Rising Awareness of Toxic Relationships: A reflection on why toxic relationships are getting more attention in light of global situations.Defining Self Within Relationships: Understanding that showing up as your whole self is crucial for healthy interactions. The Spectrum of Narcissism: Insight into how narcissistic behavior varies and its impact on relationships.Internal vs. External Responsibility: Emphasizing the importance of distinguishing between one's own emotions and those projected by others.Navigating Parental Roles & Adult Children Dynamics: Strategies for dealing with expectations set by historical family roles.Recognizing Subtle Forms of Toxicity: Acknowledging that not all toxic behaviors are overtly abusive but may still be harmful.Tools For Recovery & Empowerment:Developing a healthy relationship within oneself before addressing external onesImplementing boundariesShannon offers a free training video on her website to provide initial guidance on handling toxic relationships.She also had a support group & masterclass. These are opportunities for deeper learning and community support when dealing with these challenges.This episode provides valuable advice for anyone questioning the healthiness of their interpersonal connections while offering practical steps toward resolution and empowerment.Remember to visit HealFromToxicRelationships.com for further assistance in healing from detrimental relational patterns.Note: Always ensure you're safe when considering leaving a potentially dangerous situation; seek professional help if necessary.

ACTIONABLE TRAINING Discover the powerful and proven frameworks that work every time Image THIS IS IT! BRAIN-CENTRIC FRAMEWORKS In two half days, you'll deeply understand the Brain-centric Frameworks (formerly Basics) that align with brain processing, and deliver your communications & presentations cognitively from that point on. Your audience will retain more, understand more, and apply that knowledge immediately. This is how the brain processes information and how people love to consume it! That's right, they'll be happier. THE BRAIN-CENTRIC BASICS EXPERIENCE INCLUDES: 2-Day (4 hours per day) Live Workshop with Rich Carr Lobe-A-Phobe Exercises & Prompts Big Idea Generator plus Training Brain-centric Community: New Tools & Opportunities delivered online BONUS #1- Guest Access Pass to Bring a Friend, Colleague, or Family Member BONUS #2- Unlimited Access to the any live event in 2024 BONUS #3- Office Hours with a Brain-centric Expert Image BRAIN-CENTRIC DESIGN CERTIFICATION (BcID) The cerebral ride of your life! Certification in Brain-centric Design. Experience the groundbreaking intersection where neuroscience meets impactful, engaging, and irresistibly compelling educational and communication experiences. Lead change with intrinsic motivation and be the beacon of impactful communications & influence. The Neuroscience of Learning's unequaled individual communication advancement is the BcD Certified Brain-centric Instructional Designer (BcID) Deeply understand how the brain processes new information and how the human brain loves to learn and apply this framework to all communications immediately Cohorts are presented in our psychologically safe learning space, within the BcD model asynchronously as well as a group each week for fourteen weeks You will explore two new BcD online Challenges weekly at your own pace, reflect on your observations, and report out in our live weekly Cohorts We Are About Beautiful Baby Brains and Nature A portion of each Cohort's proceeds are gifted to The Institute For Connecting Neuroscience With Teaching and Learning. We also allocate contributions towards projects that remove carbon dioxide (CO2) from the atmosphere through Stripe Climate. Engage, Collaborate, & Ignite in a Psychologically Safe Learning Space Live, each week, spend 90-minutes with a Cognitive Learning Neuroscientist, Brain-centric Instructional Designers, Learning Scientists and harvest the collective genius. The Neuroscience of Learning's BcD Mentor/Mentee Model You need the framework to deliver Psychological Safety. This is it. Brain-centric Design (the book) Like Alice in Wonderland, you'll plunge into each subject deeply, play at your pace Image YOUR TEAM, YOUR TIME - Brain-centric Design Private Cohort Assemble those you want elevated to deliver their most high-value work, choose a time and days we can meet, and harvest the collective genius whose potential you depend on with a Brain-centric Design Private Cohort. Brain-centric's approach has yielded global success stories, such as the experience of Andrea Reindl owner of Legacy Creative, a branding & instructional design firm that recently completed certification training with their whole staff. "This training has taught us how to communicate clearer, develop better creative solutions for clients, and create training programs & brand strategies that are more effective in less time," said Reindl. "It has been a game-changer for our organization and we look forward to how it will help us grow." Influencing decisions and helping employee resilience, well-being, and productivity are transactions of psychologically safe thought, a shared belief that the team is safe for interpersonal risk-taking. These are brain processes, and Brain-centric Design is the framework you apply for how the brain processes information in a way people love to learn, communicate and thrive.

Reflections on the Big Idea: Artificial Intelligence  In this episode of The Business of Travel podcast, join host Kevin Fliess, GBTA, as he speaks with Yannis Karmis, BCD Travel and Aurelie Krau, travel tech geek and innovation consultant, to discuss the findings of the Big Ideas sessions at GBTA Europe Conference and GBTA APAC Conference and what might be on the horizon for AI in the business travel industry.   The Business of Travel Podcast is your ultimate guide to navigating the ever-evolving realm of business travel. Each week, a new episode hosted by seasoned corporate travel professionals presents an engaging and enlightening exploration of key topics shaping the world of business travel today.   The Business of Travel is the official podcast of the Global Business Travel Association. Visit www.gbta.org to learn more.  Made Possible by BCD Travel    Episode Reference Documents  The Big Idea Artificial Intelligence (AI) and What It Means for Business Travel Management Read on BCD's Website GBTA Members can read in the Hub    Host & Guest Info  Yannis Karmis, BCD Travel Aurelie Krau, Innovation Consultant Kevin Fliess, GBTA     Key Topics Discussed  Artificial Intelligence (AI) Generative AI Travel Management     If you enjoyed this episode, here are some similar shows Travel Management in the Age of AI GBTA Board View: Regional Insights on Business Travel How AI is (Re)Shaping Business Travel: A Conversation with McKinsey    Connect with GBTA   Music track is Space Jazz by Kevin MacLeod  Licensed under Creative Commons: By Attribution 3.0 License 

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: How well do truth probes generalise?, published by mishajw on February 25, 2024 on LessWrong. Representation engineering (RepEng) has emerged as a promising research avenue for model interpretability and control. Recent papers have proposed methods for discovering truth in models with unlabeled data, guiding generation by modifying representations, and building LLM lie detectors. RepEng asks the question: If we treat representations as the central unit, how much power do we have over a model's behaviour? Most techniques use linear probes to monitor and control representations. An important question is whether the probes generalise. If we train a probe on the truths and lies about the locations of cities, will it generalise to truths and lies about Amazon review sentiment? This report focuses on truth due to its relevance to safety, and to help narrow the work. Generalisation is important. Humans typically have one generalised notion of "truth", and it would be enormously convenient if language models also had just one[1]. This would result in extremely robust model insights: every time the model "lies", this is reflected in its "truth vector", so we could detect intentional lies perfectly, and perhaps even steer away from them. We find that truth probes generalise surprisingly well, with the 36% of methodologies recovering >80% of the accuracy on out-of-distribution datasets compared with training directly on the datasets. The best probe recovers 92% accuracy. Thanks to Hoagy Cunningham for feedback and advice. Thanks to LISA for hosting me while I did a lot of this work. Code is available at mishajw/repeng, along with steps for reproducing datasets and plots. Methods We run all experiments on Llama-2-13b-chat, for parity with the source papers. Each probe is trained on 400 questions, and evaluated on 2000 different questions, although numbers may be lower for smaller datasets. What makes a probe? A probe is created using a training dataset, a probe algorithm, and a layer. We pass the training dataset through the model, extracting activations[2] just after a given layer. We then run some statistics over the activations, where the exact technique can vary significantly - this is the probe algorithm - and this creates a linear probe. Probe algorithms and datasets are listed below. A probe allows us to take the activations, and produce a scalar value where larger values represent "truth" and smaller values represent "lies". The probe is always linear. It's defined by a vector (v), and we use it by calculating the dot-product against the activations (a): vTa. In most cases, we can avoid picking a threshold to distinguish between truth and lies (see appendix for details). We always take the activations from the last token position in the prompt. For the majority of the datasets, the factuality of the text is only revealed at the last token, for example if saying true/false or A/B/C/D. For this report, we've replicated the probing algorithm and datasets from three papers: Discovering Latent Knowledge in Language Models Without Supervision (DLK). Representation Engineering: A Top-Down Approach to AI Transparency (RepE). The Geometry of Truth: Emergent Linear Structure in Large Language Model Representations of True/False Datasets (GoT). We also borrow a lot of terminology from Eliciting Latent Knowledge from Quirky Language Models (QLM), which offers another great comparison between probe algorithms. Probe algorithms The DLK, RepE, GoT, and QLM papers describe eight probe algorithms. For each algorithm, we can ask whether it's supervised and whether it uses grouped data. Supervised algorithms use the true/false labels to discover probes. This should allow better performance when truth isn't salient in the activations. However, using supervised data encourages the probes to ...

Welcome to Harry Potter Theory. Today, we'll be taking a look at ALL of the KNOWN languages of magical beasts and creatures within the Wizarding World of Harry Potter, from A to Z. Sadly, there are actually no magical languages that start with A…B…C…D…or even E. In fact, the first “language” that we'll be taking a look at isn't even really a language at all… Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome to Harry Potter Theory. Today, we'll be taking a look at ALL of the KNOWN languages of magical beasts and creatures within the Wizarding World of Harry Potter, from A to Z.Sadly, there are actually no magical languages that start with A…B…C…D…or even E. In fact, the first “language” that we'll be taking a look at isn't even really a language at all… Learn more about your ad choices. Visit megaphone.fm/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome back to the BCD, Cassettes! There are some films that go hand in hand with the holiday season. These are movies that we watch every year with our families because they remind us of our childhood and the spirit of Christmas. But in the past couple decades, a different kind of holiday movie has taken the season by storm. They're known for their cheesy lines, simplistic plotlines, and by-the-numbers predictability. Many fans claim to watch these made-for-TV movies as a guilty pleasure, while others have fully embraced their comforting tropes. We're talking, of course, about Hallmark Christmas movies.   You know the deal: He's a small town business owner of some kind (Christmas trees/coffee shop/bakery) and she's a successful woman from the city with a vague job title. Why don't we know what she does? Well, that's because it doesn't matter; she's quitting that job by the end of the movie. They were lovers once, or maybe she left him at the altar, and this Christmas, they may just find their way back to each other again. Each Christmas, these cookie cutter movie plots dominate social media because they are an easy target. But this got us wondering, when did it all start? Over the last twenty years or so, Hallmark essentially invented their own genre, which is honestly pretty impressive. So today, we're getting a better look at the history of Hallmark Christmas movies and discussing the formula that has made them so successful.    So grab your favorite movie snack and cuddle up next to a roaring TV, it's time to talk about Hallmark Christmas movies!

Join Drs. Skolnik and Wettergreen, along with special guests: Aaron Sutton, LCSW, BCD, CAADC - Chief Wellness Officer for Graduate Medical Education at Abington-Jefferson Health, and Jordan Burkey, an individual living with diabetes. They will be discussing effective strategies to navigate the winter season and holiday time while living with diabetes. Tune in to learn how to overcome any challenges that may come your way! Share your diabetes story with us by leaving a message at (703) 755-7288. You might be featured on a future Diabetes Day by Day episode.

The Business are back in the house along with BCD champion Roger Sears to discuss the weeks wrestling bullshit! Does anyone really care if NWA are pearl harbouring their TV deal with fictional cocaine?! Did anyone watch WWE Crown Jewel? Why does Anton hate Logan Paul so much?! All this and alot more discussed on this weeks extremely stupid podcast! UNCENSORED, UNEDITED AND 18+ WRESTLING DISCUSSION! #GETPLUGGEDIN The Business Facebook: https://www.facebook.com/the.business.podcast PWT: ⁠https://www.prowrestlingtees.com/wrestleplug⁠ Aeron Nix Design: ⁠https://www.facebook.com/AeronNixDesign/⁠ Wrestle Plug Twitter: ⁠https://twitter.com/WrestlePlug⁠ Wrestle Plug Insta: ⁠https://www.instagram.com/wrestleplug/⁠ Wrestle Plug Facebook: ⁠https://www.facebook.com/WrestlePlug/⁠ Youtube: https://youtu.be/XBxDuFDeN2g

This week's news highlights Discord's deep-dive into how they've scaled their servers to support millions of concurrent users, leveraging Elixir's power. We cover how the Oban notifier has evolved to include Phoenix.PubSub and Redis integration, allowing more flexibility for your job processing needs. LiveView Native's tutorial experience looks promising to make mobile development smoother and more intuitive. Plus, we cover the Livebook PR merge upgrading to the Bandit library and more! Show Notes online - http://podcast.thinkingelixir.com/177 (http://podcast.thinkingelixir.com/177) Elixir Community News - https://discord.com/blog/maxjourney-pushing-discords-limits-with-a-million-plus-online-users-in-a-single-server (https://discord.com/blog/maxjourney-pushing-discords-limits-with-a-million-plus-online-users-in-a-single-server?utm_source=thinkingelixir&utm_medium=shownotes) – Discord blog post detailing the scaling of individual Discord servers and the technical challenges involved. - https://github.com/discord/manifold (https://github.com/discord/manifold?utm_source=thinkingelixir&utm_medium=shownotes) – GitHub link to Discord's opensource Elixir library "Manifold" used for batch message passing between nodes. - https://www.youtube.com/watch?v=HP86Svk4hzI (https://www.youtube.com/watch?v=HP86Svk4hzI?utm_source=thinkingelixir&utm_medium=shownotes) – Chris Grainger discusses using Elixir + Phoenix + Nx in production with machine learning on the BEAM. - https://github.com/livebook-dev/livebook/pull/2316 (https://github.com/livebook-dev/livebook/pull/2316?utm_source=thinkingelixir&utm_medium=shownotes) – A Livebook PR titled "Upgrade to bandit" merged by José Valim, signifying an endorsement for the Bandit library. - https://twitter.com/cvkmohan/status/1719489327925694682 (https://twitter.com/cvkmohan/status/1719489327925694682?utm_source=thinkingelixir&utm_medium=shownotes) – Discussion on Twitter about using Bandit as an upgrade for a Phoenix app. - https://elixirstream.dev/gendiff/phx_new/19CBA027FA97E2873CC24093F6AC1820 (https://elixirstream.dev/gendiff/phx_new/19CBA027FA97E2873CC24093F6AC1820?utm_source=thinkingelixir&utm_medium=shownotes) – A flag added to elixirstream.dev for diffing generated output, introduced in Phoenix 1.7.8. - https://github.com/sorentwo/obannotifiersphoenix (https://github.com/sorentwo/oban_notifiers_phoenix?utm_source=thinkingelixir&utm_medium=shownotes) – Release of a new Oban notifier powered by Phoenix.PubSub, compatible with OTP and now able to use Redis. - https://twitter.com/bcardarella/status/1720179762088272080 (https://twitter.com/bcardarella/status/1720179762088272080?utm_source=thinkingelixir&utm_medium=shownotes) – Tease of the upcoming LiveView Native v0.2 and its tutorial experience using Livebook. - https://podcast.thinkingelixir.com/174 (https://podcast.thinkingelixir.com/174?utm_source=thinkingelixir&utm_medium=shownotes) – Previous interview about DockYard's BeaconCMS - https://twitter.com/bcardarella/status/1721172482298663214 (https://twitter.com/bcardarella/status/1721172482298663214?utm_source=thinkingelixir&utm_medium=shownotes) – Twitter post discussing the 'Variants' feature for A/B/C/D/etc. page variant testing in BeaconCMS. - https://twitter.com/NervesMeetup/status/1721389396417728782 (https://twitter.com/NervesMeetup/status/1721389396417728782?utm_source=thinkingelixir&utm_medium=shownotes) – Announcement tweet for the next Nerves embedded systems meetup. - https://www.meetup.com/nerves/events/290189609/ (https://www.meetup.com/nerves/events/290189609/?utm_source=thinkingelixir&utm_medium=shownotes) – Meetup link for the Nerves embedded systems event featuring a walkthrough by Alex McLain. Do you have some Elixir news to share? Tell us at @ThinkingElixir (https://twitter.com/ThinkingElixir) or email at show@thinkingelixir.com (mailto:show@thinkingelixir.com) Find us online - Message the show - @ThinkingElixir (https://twitter.com/ThinkingElixir) - Message the show on Fediverse - @ThinkingElixir@genserver.social (https://genserver.social/ThinkingElixir) - Email the show - show@thinkingelixir.com (mailto:show@thinkingelixir.com) - Mark Ericksen - @brainlid (https://twitter.com/brainlid) - Mark Ericksen on Fediverse - @brainlid@genserver.social (https://genserver.social/brainlid) - David Bernheisel - @bernheisel (https://twitter.com/bernheisel) - David Bernheisel on Fediverse - @dbern@genserver.social (https://genserver.social/dbern) - Cade Ward - @cadebward (https://twitter.com/cadebward) - Cade Ward on Fediverse - @cadebward@genserver.social (https://genserver.social/cadebward)

Episode 101. In this episode we discuss BCD final thoughts on Alan Wake 2, Star Wars: Jedi Survivor, Call Of Duty MW3, Zelda Live Action, Epic Games Store Not Making A Profit and much more. Intro: 00:00Alan Wake 2: 11:26Star Wars Jedi Survivor: 27:00Call Of Duty MW3: 40:25Blizzcon Recap (Overwatch 2): 01:06:11Ubisoft Layoffs People For "Efficiency": 01:13:16Epic Games Store Not Profitable: 01:19:00Fortnite Doing Numbers: 01:26:50Zelda Live Action: 01:32:38

In this exciting episode, Norb Svanascini and Al Edwards discuss what has become known as the BCD connection. All human beings experience the “B' for birth, and eventually the “D” for death. But what's in the middle is what makes all the difference. Get ready to be inspired as you learn what the “C” is all about. The Magic of Positive Thinking is brought to you by Americaneagle.com Studios; follow today for exciting new episodes!

When you want something strange on your podcast player, who you gonna call?? Hopefully the BCD! Welcome to our special Halloween episode of the Boo Case Diaries, where we cover one of the most popular spooky movies of ALL TIME: Ghostbusters!  Show notes and sources available: https://www.blackcasediaries.com/ We're now on YouTube! 

Hey Cassettes and welcome back to the BCD! As summer vacation comes to a close, we decided to revisit one of our favorite summer classics: The Sandlot (1993)! Come join us as we laugh and learn all about the 90s cult hit that gave us quotable lines like, "you're killin' me, Smalls!" Head on over to https://www.blackcasediaries.com/ for show notes and sources.  Thanks for listening!

How do you heal after being ghosted after a toxic relationship? How do you know if you're in a harmful or toxic relationship right now? Listen as Shannon Petrovich, LCSW, LISAC, BCD, shares: - How to detect the red flags of a harmful relationship- Ways to navigate gaslighting, love bombing, and trauma bonding- Why ghosting is a grand manipulation- What to do if your ghost comes back- How to heal after being ghosted in a harmful relationshipGretta and Shannon's conversation also touches on narcissism, whether or not to block your ghost, and how to rebuild your sense of self. Connect With Shannon Petrovich, LCSW, LISAC, BCD :Website: No Foggy DaysShannon's Book:  Out of the FOG, into the CLEAR; Journaling to Help You Heal from Toxic RelationshipsTherapist Talks YouTubeConnect with Gretta:New! Take Your Power Back WorkshopFree Guide: What to Say To Your GhostFree and Private Facebook Support Group |  Instagram | copingwithghosting.comMusic: "Ghosted" by Gustavo ZaiahDisclaimer:  This information is designed to mentor and guide you to cope with Ghosting by cultivating a positive mindset and implementing self-care practices. It is for educational purposes only; it solely provides self-help tools for your use. Coping With Ghosting is not providing health care or psychological therapy services and is not diagnosing or treating any physical or mental ailment of the mind or body. The content is not a substitute for therapy or any advice given by a licensed psychologist or other licensed or other registered professionals. Are you ready to move forward after being ghosted? Are you tired of worrying, stressing, and struggling to find answers? If you want to regain control of your thoughts and feel more at peace, there's a solution for you. For less than the cost of one coaching session, you can download the new Take Your Power Back Workshop. In it, Gretta and Coach Estee K. will help you better understand why ghosting happens, ways to feel better now, and actionable steps to take your power back. Your purchase will help support this podcast, so it's a win-win! Note to All Listeners: Ghosting is defined as: The practice of ending a personal relationship with someone by suddenly and without explanation withdrawing from all communication (Oxford Languages).When you leave an abusive situation without saying "goodbye," it's not ghosting, it's "self-protection." When you quietly exit a relationship after a boundary has been violated, it's not ghosting, it's "self-respect."

There's no place like home, Cassettes! We're back again with another full length episode of the BCD!! Join us this week as we learn all that we can about the history behind The Wizard of Oz (1939).  Thank you for listening!   You can read our show notes and sources at https://www.blackcasediaries.com/ Patreon: https://www.patreon.com/blackcasediaries Instagram & Threads: @blackcasediariespodcast

Roger Sears was a great wrestler when he last spent time at the Wrestle Plug but since then hes captured gold in the most vaunted of playgrounds that is BCD Wrestling. He opens up candidly with Aeron about his time spent with BCD and under the learning tree of Jay Knox. He also discusses the harsh realities of working for a blacklisted company, his dream opponents, what he thinks of the current crop of BCD stars and alot more! #GETPLUGGEDIN Roger Sears Facebook: https://www.facebook.com/RSearspw Roger Sears Insta: https://www.instagram.com/r.sears.prowrestler/ PWT: ⁠https://www.prowrestlingtees.com/wrestleplug⁠ Aeron Nix Design: ⁠https://www.facebook.com/AeronNixDesign/⁠ Wrestle Plug Twitter: ⁠https://twitter.com/WrestlePlug⁠ Wrestle Plug Insta: ⁠https://www.instagram.com/wrestleplug/⁠ Wrestle Plug Facebook: ⁠https://www.facebook.com/WrestlePlug/⁠

Culture makes all the difference between teams that thrive and those that struggle. We look to leaders to set the example of culture, but culture is really the responsibility of every member of the team. In this episode of The Forward Thinking podcast, host Stephanie Barton, VP of Marketing and Communications at FCCS welcomes speaker and consultant Derek Avera for a look at the critical intersection of leadership, culture and behavior. Derek will be speaking at the upcoming FCCS FORUM for Ag Lending, and today he offers listeners a glimpse of what he will be sharing there, including the importance of culture, the factors that have the greatest impact on culture, and conversation starters for building a greater team culture today.    Episode Insights Include:   Who is responsible for organizational culture? The short answer is that everyone is responsible for the culture. Leaders first set the tone and the example for a performance pathway. Leaders create the culture that drives the behavior that produces results. The entire organization is responsible for what they commit to the culture. Leaders set the tone with their energy and language.   The relationships between leadership, culture and behavior These three are tethered together and must be aligned. If leaders want better results, they need better behavior. Better behavior is a product of better culture, which comes from better leadership. The sum of these three facets produces results in any organization.   The biggest effects on culture Leadership and behavior can be extremely positive or negative. Realistic optimism and resilience are both critical for leaders. The behavior of the entire team can drive the desired results.   How is positive culture built? Intentional, disciplined effort is the first necessary step to creating a positive culture. Impulses have to be limited and emotions need to be monitored. Working outside of our comfort zones will help teams build new skills.   Conversation starters for culture conversations How is the culture of the team affecting the performance of the team? What does aligned culture look and sound like? How can you align your team to get the results you are seeking?   The power of common vocabulary Short terms and phrases can be used to align team vision and culture. Consider your own ‘20 square feet' and ‘BCD' (blame, complain, defend). Common vocabulary allows everyone to quickly remember and remind about desired culture as needed.   This podcast is powered by FCCS.   Resources   Learn more about the upcoming FCCS FORUM for Ag Lending - https://www.fccsconsulting.com/conferences/forum   Connect with Derek Avera - https://focus3.com/member/derek-avera/   Get in touch   info@fccsconsulting.com    

    Drs. Diwakar Davar and Jason Luke discuss KEYNOTE-716, KEYNOTE-942, RELATIVITY-047, and other key advances in melanoma, including the promise of mRNA vaccines in melanoma and potentially other cancers, as well exciting advances in neoadjuvant therapies across malignancies featured at the 2023 ASCO Annual Meeting. TRANSCRIPT  Dr. Diwakar Davar: Hello, and welcome to the ASCO Daily News Podcast. I'm your guest host, Dr. Diwakar Davar. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh Hillman Cancer Center. I'm delighted to have my colleague and good friend Dr. Jason Luke on the podcast today to discuss some practice-changing studies and other advances in immunotherapy that were featured at the 2023 ASCO Annual Meeting. Dr. Luke is an associate professor of medicine, the director of the Cancer Immunotherapy Center, as well as the associate director of clinical research at the University of Pittsburgh's Hillman Cancer Center.     You can find both of our disclosures in the transcript of this episode, and disclosures of all guests on the ASCO Daily News Podcast are available on our transcripts at asco.org/DNpod.   Jason, there was a lot of exciting data in the immunotherapy space highlighted at the Annual Meeting, and it's great to have you back on the podcast to discuss some of this work.   Dr. Jason Luke: Thanks for having me.    Dr. Diwakar Davar: So, the abstracts that we had selected have several key themes. We'll be covering some of the early advances in melanoma in the stage 2 and stage 2B/C space with KEYNOTE-716. I think this is a study that you know a little bit about seeing you are the presenting author and the principal investigator for the study, as well as the pivotal KEYNOTE-942 trial. And then going on to themes with using third-generation checkpoints, neoadjuvant therapy in non-small-cell lung cancer, and cutaneous squamous cell carcinoma.    But we'll start with KEYNOTE-716. So, this is LBA9505, the study which evaluated pembrolizumab versus placebo as adjuvant therapy in stage 2B and stage 2C melanoma patient population for which historically there was no real effective therapy other than remotely interferon. And these are the final results of the DMFS analysis from this phase 3 trial. So, Jason, what are your thoughts about this, and can you contextualize the results relative to the recent publication?   Dr. Jason Luke: Thanks. I think the important point to level set on this was just a few years ago; this was a population of patients that we didn't treat in clinic. In fact, sometimes they weren't even referred to medical oncology for evaluation. And that was despite the fact that we knew from historical data that the risk of melanoma-specific survival, death from melanoma, was just as high for this population of patients as it was for the patients with stage 3 melanoma, where obviously adjuvant immunotherapy has been a standard for quite some time. And so we launched this clinical trial, KEYNOTE-716. It was a global, randomized phase 3 study of almost 1,000 patients, randomizing patients to either get pembrolizumab or placebo. Importantly, these patients being those with deep primary lesions, stage 2B and 2C with negative sentinel lymph node evaluation.    People will recall that this study hit its primary endpoint on the first protocol-specified analysis at a year. And what we updated at ASCO this year was the final analysis of distant metastasis-free survival. Obviously, an important secondary endpoint because if patients eventually going to develop metastatic disease and pass away, it's the distant metastasis that we worry about. And what we saw in this trial with a landmark 36-month follow-up median of 39 months was that the benefit was increasing. In other words, the magnitude of the hazard ratio change was increasing over time as would be expected, such that at this analysis there was a 41% reduction in the risk of distant metastasis for patients treated with pembrolizumab versus placebo. And we saw a consistent benefit in the recurrence-free survival also out through that same period of time and importantly no change in the safety summary with of course the adverse event profile of pembrolizumab being what it is and well understood across oncology.    So I think these are very important data because they really kind of set the stage for the field. It is now the case that at least discussing adjuvant therapy for patients with stage 2B and 2C is the standard of care; it should be offered to all the patients. Of course, it's always a risk-benefit about whether or not patients want to pursue adjuvant therapy versus consideration of treatment at the time of recurrence. But in my clinic at least, many patients do prefer to try to eliminate the possibility of recurrence and distant metastasis as much as possible.    So I think these are very important data because they really level set the field for what to expect in this population of patients and then they also start to set the table for what's going to come after this. And that's going to be sort of the next step in our conversation here because the next generation of adjuvant studies in melanoma are now going to think about all of melanoma in the adjuvant setting as really one entity, starting from stage 2B going all the way through stage 4 resected. And that'll be relevant actually as we talk about the next abstract that will come in this discussion.   Dr. Diwakar Davar: Just to underscore, positive RFS data, positive DMFS data, and now this therapy has currently got regulatory approval in this investigation and is approved in the United States and certainly in Europe and Australia. One interesting point that we will probably have to contend with, and some of the listeners may be thinking about, is overall survival. So the last adjuvant study that demonstrated overall survival benefit was actually ipilimumab, and increasingly, the Illuminati in melanoma do not believe that we will ever see OS benefit in this disease going forward, even though it has to be an endpoint in all registration phase 3 trials. So, Jason, what are your thoughts about whether or not we'll have a positive OS readout, and even if we don't, why this is still a very important advance in this disease at this time?   Dr. Jason Luke: Your points are well taken. I think it's unclear, probably trending towards unlikely, that we would see an overall survival advantage in this trial given that we have not seen that in the stage 3 adjuvant studies. Now people can debate if, whether or not overall survival is the only meaningful endpoint for patients. I personally do not believe that's true. And to me, preventing recurrence has a value in and of itself, whether or not that's connected to overall survival. And part of the reason that I say that is that for an average patient, the median patient on a trial, of course, we can tell them treatment now, treatment later. It's a wash when you look at the overall study. And yet at the same time, for an individual person who's facing melanoma or cancer, generally they're not going to be the average patient; they're going to be one patient. And it's very possible they could end up with the type of recurrence that in fact is not highly treatable at that time.     So I think that's really the nuance that goes into those adjuvant discussions. The regulatory endpoints have been recurrence in melanoma for a long time. And I think it's important that patients understand the pros and the cons of each. The complexity in adjuvant therapy and neoadjuvant therapy is you don't necessarily know that you had to have it. You're only really going to know whether or not it didn't work if you recur later on. But to me and in my clinic, most patients are willing and interested to want to pursue those therapies in the perioperative setting to try to reduce the possibility of ever developing metastatic disease.    Dr. Diwakar Davar: Excellent. So I think key advance [is] positive DMFS data to add to the earlier reported RFS data and truly practice-changing.     So, moving on to the next study, LBA9503. This is the phase 2 trial of the Moderna vaccine. This is the trial that almost every medical oncologist knows intimately or has been called about by either the press or patients. So what is this study? This essentially is a phase 2 trial evaluating the personalized cancer vaccine PCV Moderna, made by Moderna, the mRNA vaccine, that is being studied in combination with anti-PD-1 pembrolizumab in the stage 3 BCD and stage 4 resected setting. And so there are really two very interesting results here because this is an update of the RFS data that was presented at AACR earlier this year, which was positive. What are your takes on the DMFS results, and maybe a quick blurb on how is this vaccine generated for those who may not be aware of this particular platform?    Dr. Jason Luke: Yeah, certainly. So this individualized neo-antigen therapy, as we're now calling it, is a technology platform that allows us to develop an individualized treatment for each patient based on their own cancer. So taking the actual tumor specimen, whole exome sequencing is performed to try to identify changes in the DNA, and then through a reasonably complex bioinformatic pipeline, those mutations that are likely to generate proteins that can be bound within class 1 MHC molecules are then identified in the computer and then synthesized with an mRNA, very similar to the way that the COVID vaccines were made. And then that becomes the actual drug.    So in the clinical trial, which was KEYNOTE-942, about 160 patients were randomized 2 to 1 to receive either pembrolizumab for a year as per standard adjuvant therapy but then with the addition of the individualized neoantigen therapy starting with dose 3 and throughout the rest of the year versus the control arm of pembrolizumab as the standard of care. As you mentioned, the recurrence-free survival were highly positive in this trial when it was first presented earlier this year, and at the updated ASCO we see the 18-month RFS in which the hazard ratio continues to be maintained. But I think most impressively is that distant metastasis-free survival, where we saw an even greater advantage for distant metastasis-free survival – hazard ratio here being 0.35. And so that's a huge advantage for distant metastasis-free survival in this population of patients.     And very interestingly in the clinical trial, when you follow the Kaplan-Meier plots, what you see over time is that they overlap almost the entire first year. And it's really at about a year, basically after the vaccine has had time to kick in and these neoantigens have been identified, that we then start to see the separation of the curve, which looks very flat over time. And so I think this is a very, very exciting kind of technology platform and very exciting results because there was minimal increase in toxicity – just at the site of the local injection – for the addition of the individualized neoantigen therapy.    And beyond that, hypothetically, this is not necessarily just a melanoma thing. So, of course, based on these phase 2 results, a phase 3 clinical trial called KEYNOTE-V940 is going to be launching later this year to compare pembrolizumab versus pembrolizumab plus this V940 individualized neoantigen therapy. And we're very, very excited in the field to see what those results will look like because the concept here is you could really, really enhance adjuvant therapy with this kind of an approach. Meanwhile, we're just about to talk in a little bit about all the exciting things happening in the neoadjuvant space as well. And with no increase in toxicity, obviously, that looks really good.    Suffice it to say that this technology is not specific to melanoma but rather could be applied almost to any cancer where we think about an adjuvant therapy platform. So I think the results are very, very exciting. It is a phase 2 study and it does have some caveats about not being the largest study and some other things, but you can't help but be impressed by the data that have been presented here so far.   Dr. Diwakar Davar: One important plug, I guess, in addition to that is that you mentioned that there's data using the platform in other diseases. And one really exciting paper that came out recently was Dr. Vinod Balachandran's paper; for those who haven't read it, it's in Nature, and really in a very provocative proof of concept study, they studied the platform, the vaccine plus checkpoint inhibitor therapy plus chemotherapy in a highly adverse tumor patient population. So these are patients with resectable pancreatic cancer who had the vaccine generated from pancreatic cancer that was resected after Whipple surgery. And extraordinarily, out of the 16 patients who had immune responses, 8 of them did not have relapse at a median follow-up of almost a year and a half, which is really quite extraordinary given the lack of really any effective drug outside of chemotherapy in that setting.     So, the point that you're making regarding the benefit of this therapy, suggesting that it could potentially be extended to not just melanoma, potentially other tumors such as highly immunogenic tumors, and potentially even nonimmunogenic tumors such as pancreatic cancer, really suggests that this is going to be a very exciting landscape. And potentially this area, adjuvant therapy and neoadjuvant therapy, like we'll talk about, is potentially an area in which other drugs and potentially combinations will be developed.    So next, we will be discussing 3 abstracts evaluating the theme of combinations, and these abstracts are 9501, 9502, and 4010. Abstract 9501 is an evaluation of the combination of fianlimab and cemiplimab anti-LAG-3 and anti-PD-1, respectively, in advanced melanoma, specifically focusing on the post-PD-1 experience in this disease by Dr. Omid Hamid. 9502 is the updated 2-year survival results from RELATIVITY-047, which evaluated nivolumab and relatlimab against nivolumab alone in frontline metastatic melanoma. And Abstract 4010 are the results from the MORPHEUS platform study, specifically looking at tiragolumab and atezolizumab in patients with advanced unresectable HCC.    But focusing on 9501 and 9502, Jason, what do you make of the combination of fianlimab and cemiplimab post-PD-1 setting?   Dr. Jason Luke: I think the data look very intriguing for this second combination of PD-1 and LAG-3 combination. When nivolumab and relatlimab, the approved LAG-3 inhibitor, kind of burst on the scene a couple of years ago, it was somewhat to the surprise of a lot of people in the community who had really come to think that while PD-1 and CTLA-4 were core molecules for therapeutics and cancer, that we just weren't ever really going to see something else come along in checkpoint blockade. And so nivo and rela got approved. We'll talk about them again in a second. But the data now coming forward for another PD-1 LAG-3 combination, again with cemiplimab PD-1 and fianlimab LAG-3, looks very, very promising.    So in Abstract 9501, they updated a phase 1 expansion cohort, phase 2 cohort looking at patients across the various different settings. And whereas in the treatment naive frontline metastatic setting they had previously described about a 63% response rate, they saw a similar level of response rate in patients who had previously gotten adjuvant anti-PD-1, had a period of time off treatment, and then were treated again. And that was reassuring because it suggested that this is still an active combination even with prior exposure to IO in the past.     Now, the thing that I found to be the most interesting about this combination was whereas with nivo and rela, at least from the RELATIVITY-047 phase 3 trial, it looked like there was less benefit in some of the high-risk population cohorts, at least for this combination in early testing for cemi and fian; like we talk about it sometimes, we saw there was a high response rate even in patients with liver metastases and some other high-risk features. And so I think this combination looks quite potent, and I'm very excited to see what the data will look like. I think it's very unlikely we'll ever actually get a randomized trial of two PD-1 LAG-3 combinations against each other. But suffice it to say that the data we've seen so far for fianlimab LAG-3 with cemiplimab PD-1 looks very intriguing. It certainly justifies the frontline metastatic phase 3 and the adjuvant phase 3 trials that are already in planning or ongoing.   Dr. Diwakar Davar: So one thing to consider is on the RELATIVITY-020 trial – the early trial that was led by Dr. Ascierto that really took a long time to read out – the response rate in patients with prior checkpoint inhibitor therapy was quite low. In fact, the data was quite surprising, as you'd mentioned that we had even seen this movement in the frontline setting because the response rate by BICR was only about 12%. So do you feel like the 2 LAG-3 inhibitors are fundamentally different? And if so, can you speculate as to why that might be? Again, with the caveat to the fact that these are very early data and we don't have enough information. And maybe we can also talk a little bit about the 2 pending trials that are ongoing in the advanced and adjuvant therapy landscapes perspective.   Dr. Jason Luke: I think we don't have enough data yet to truly understand whether or not they're really different. The trials that have been run so far are so different that it's hard to compare things back and forth. You can notice that the dose, the milligram dosage of fianlimab in terms of anti-LAG-3 is quite a bit higher, like a log fold higher almost than with relatlimab. And so there's some question of whether or not just merely more drug-blocking LAG-3 might in fact be more efficacious relative to the dose that's approved for relatlimab in melanoma. But beyond that, I think the data hold up very well for this new combination, again noting all the caveats about cross-trial comparison to, say, it looks to be at least as potent, possibly more potent than the relatlimab combination. But again, I think probably we need to see the data from randomized trials and how that fits into the landscape when the trials actually read out because there's a lot of things going on in melanoma that are likely to change between now and then.   Dr. Diwakar Davar: So just to draw people's attention, there are actually 2 ongoing pivotal phase 3 trials: fian plus cemi versus pembro in patients with advanced metastatic and locally advanced, previously untreated melanoma, as well as an adjuvant trial of the combination against pembrolizumab. Again, highly high-risk resected melanoma. These trials are ongoing. We don't have the results yet and we are looking forward to them.    Now, 9502, a 2-year RELATIVITY-047 result presented by Dr. Hussein Tawbi.    Dr. Jason Luke: So this is the study we were just alluding to before, the randomized phase 3 study of nivolumab versus nivolumab plus for relatlimab. To me, the most useful data sort of updating with this two-year survival follow-up is to show the maintenance of benefit between the 2 arms. And so, consistent with what we saw with nivolumab and ipilimumab, there seems to be a persistent delta between the arms for both progression-free and for overall survival out over that extended period of time, where we can see with that updated data now, at 2 years, that it's 52% of patients still alive on the relatlimab combo versus 42 with nivolumab. And it does seem like this is probably a higher-risk population of patients than participated in CheckMate-067.    So it's a little bit difficult to compare the landmarks except to notice that that difference between the control and experimental groups is consistent over a long period of time and that there were no new safety signals either, and so that was also reassuring. To me, the most interesting nugget of data in the abstract, though, is to look at what happened to patients after they were on the first-line treatment. So one of the big questions in our field is really “If patients get nivolumab and relatlimab upfront, what should they get after that?” Should they then get nivo plus ipi, or vice versa? And I think we don't have an answer clearly to that question just yet.    There was an important letter to the editor of the New England Journal now going on about a year ago by Alex Menzies and colleagues that suggested that the use of ipilimumab was attenuated, the utility of it, after a prior exposure to nivolumab plus relatlimab. They quoted a response rate on the order of only about 10% for patients who got an ipilimumab-containing regimen after initial LAG-3. In the data from Hussein Tawbi at ASCO, however, in a small number of patients, caveat, the response rate was more in sort of the low 20% range, 22% to 25%. And so that would be a much more meaningful and important sort of consideration. If we do have independent activity, then lining up sequential therapies and the toxicities associated with each will become increasingly important as we think about how to maximize these kinds of treatments for our patients, but important longer-term data to show that the benefit is holding up and it's safe, and some new insights into what to do after progression on one of these regimens.    Dr. Diwakar Davar: So, pivoting slightly to combinations, we are going to be discussing a combination of TIGIT plus checkpoints. So tiragolumab is the FC-active TIGIT inhibitor from Regeneron-Roche and this is currently in multiple pivotal phase 3 trials, several of which have been negative, including SKYSCRAPER-01 in non-small cell lung cancer and SKYSCRAPER-03 in small cell lung cancer. The MORPHEUS platform trial essentially is a platform study evaluating multiple different combinations, in this case in liver cancer. And so we have a very interesting Abstract 4010, which is giving us an early readout of the evaluation of tiragolumab plus atezolizumab along with bevacizumab in unresectable, locally advanced or metastatic hepatocellular carcinoma giving us a result that is a little different from what we had seen from the prior negative results of TIGIT. So Jason, what do you make of these early results in the advanced HCC setting?   Dr. Jason Luke: I think these are cautiously intriguing results to really highlight the point is the third checkpoint possibly being LAG-3, now a fourth checkpoint maybe with TIGIT, but with all the caveats that you talked about. In this study, the flow is that there's a continuously accruing control arm which in hepatocellular carcinoma is a combination of atezolizumab plus bevacizumab, and then other arms are added where you add in a third agent. In this case, it's the anti-TIGIT tiragolumab. And in an intriguing fashion, the response rate to the triplet was 42.5% compared to the doublet which was only 11%. So that's a pretty big difference in this population.     Now, it wasn't the largest study, only 58 patients, but it was a randomized clinical trial. And so I think those data really make people kind of open their eyes again. It's worth a little bit of a caveat here that HCC is an unusual cancer in that what is deemed to be unresectable and therefore amendable to systemic therapy is a moving target and that requires multidisciplinary evaluation of patients. And so I think a larger number of patients would really be needed to fully understand this. But certainly, a fourfold increase in the benefit or in terms of response rate looks quite intriguing.    I think the other piece of this is to be just cautious a little bit was when the initial data in non-small cell lung cancer in the CITYSCAPE study came forward, and they looked roughly sort of like this: There was more than a doubling in the PFS and the response rate, which is what triggered all of those phase 3 studies. So to me, this is enough to continue to be very interested in TIGIT as a therapeutic target. And there are many phase 3 trials already ongoing. And so I think, I'm cautiously optimistic that some of those actually will be positive and we could see more movement around TIGIT becoming a standard of care agent.    Dr. Diwakar Davar: To your point about TIGIT being an interesting target, recent data looking at the neoadjuvant landscape in melanoma from Merck, with Merck, also FC-active TIGIT and also some data from authors looking at that TIGIT also presented in this case at ASCO specifically from the ARC-7 study. So very interesting target. Several pivotal trials have been announced. Do you know of any trials that are ongoing in the adjuvant setting in other diseases?   Dr. Jason Luke: Well, as you alluded to, the vibostolimab data in melanoma for TIGIT in the neoadjuvant setting was interesting. And in fact, that has been enough to trigger a global, randomized phase 3 adjuvant study of pembrolizumab and vibostolimab versus pembrolizumab in melanoma. And that sort of takes us back to the beginning of our discussion here, building on the KEYNOTE-716 data. So, yes, TIGIT will be moving forward in the adjuvant space in melanoma and obviously at a static setting for several different tumor types with a PD-1 or PD-L1 backbone.   Dr. Diwakar Davar: So now pivoting towards neoadjuvant therapy and non-small cell lung cancer. The standard of care in this setting was established by the CheckMate-816 trial that essentially established nivolumab plus chemotherapy in the setting of resectable non-small cell lung carcinoma path. Response rate in this setting is approximately 21%. And we have several studies that are essentially looking at novel combinations or in this case, different PD-1 inhibitors in this setting. So Abstract 8500 essentially looked at nivolumab plus relatlimab from a NEOpredict-Lung trial. Jason, do you want to tell us a little bit about this?    Dr. Jason Luke: Yes, I think this is a very interesting study and that this is sort of our first peek at targeting LAG-3 in the context of lung cancer. So obviously we talked about LAG-3 for melanoma. Although the audience is probably aware that there have been neoadjuvant data for LAG-3 with relatlimab in melanoma that substantiated the phase 3 data for the metastatic setting. So one of the questions as we start to apply the LAG-3 in other diseases would be, “Do we see it hold up in both metastatic disease and in the neoadjuvant space?” But in this study, while there were no changes in the safety profile; it didn't impact on whether or not patients could have surgery. There really didn't look to be a big difference in this study between nivolumab and nivolumab plus relatlimab, with the major pathologic response as you alluded to right around 30% for both arms.    Now, it wasn't really the biggest study, but that's certainly quite a bit in contrast with what we've seen in melanoma, where with a PD-1 inhibitor you get again 25%-30%, but with adding on LAG-3, that pushes you up closer to 60%. So I think these were very interesting data that probably put a little bit of an eyebrow raise to say, “Well, let's see what happens in the metastatic setting in lung cancer with the addition of relatlimab LAG-3 on top of a PD-1.” I think it might not be quite so straightforward as what we saw in melanoma, but we'll look forward to those results because those phase 3 trials in metastatic lung cancer should be maturing sometime in the next year or two.   Dr. Diwakar Davar: The theme of neoadjuvant therapy non-small lung cancer, LBA100, which has again previously been discussed in an episode of this podcast by Dr. Jack West and Dr. Velcheti is KEYNOTE-671. And this is a study essentially that looked at pembrolizumab or placebo with platinum-based chemotherapy doublet and followed by resection. So again, a direct parallel to CheckMate-816. What do you make of the results that were reported by our colleagues in this setting, Jason?   Dr. Jason Luke: So not to rehash this, because our colleagues in the lung cancer group have already discussed this at length and obviously they're experts in that disease, but we'll just note that there was a threefold increase in major pathologic response, which turned into a major advantage for event-free survival. And so I think this is at least the third PD-1, PD-L1 combination regimen for neoadjuvant lung cancer that looks very, very promising. It certainly, to me, seems like neoadjuvant consideration really should be the standard of care already moving forward.   To me, what the big question that is left with is “Do we still need the adjuvant component after we give the neoadjuvant?” So, some of the trials are including neoadjuvant and adjuvant, some of them are only neoadjuvant. And I think that's going to be a really important question as we move into the future, both in terms of what is that contribution of the adjuvant component, and then again, going back to earlier in our discussion here, if there could be a major advantage to adding individualized neoantigen therapy, maybe it is important to have both. But I think that's one of the big questions we have to get teased out by the field over the next couple of years.   Dr. Diwakar Davar: And finally pivoting towards cutaneous squamous cell carcinoma. We have 2 abstracts discussing perioperative therapy. So cutaneous squamous cell carcinoma is a high-TMB tumor. The median tumor mutation burden in this disease is threefold that of melanoma. This is a disease in which checkpoint inhibitor therapy is approved as a single agent both with pembrolizumab and cemiplimab on the basis of nonrandomized phase 2 trials. And increasingly, there has been early development in the perioperative setting. The first data in this space came from our colleague Dr. Gross at MD Anderson, who reported in a small, nonrandomized phase 2 trial of 20 patients, a path CR rate with two cycles of cemiplimab at approximately 50%.    A larger multi-institutional phase 2 trial demonstrated that a longer duration of perioperative therapy of four cycles or 3 months of cemiplimab did not particularly improve the path response rates. The response rates were similar at approximately 50% as well. And what we have right now are 2 other trials. The first is the MATISSE trial, Abstract 9507 ,that evaluated nivolumab or nivolumab plus epilimumab in this disease. And the other one was the NEO-CESQ trial, or Abstract 9576, that evaluated neoadjuvant plus adjuvant therapy that's cemiplimab in the high-risk patient population. So we're starting with 9507. Jason, what do you make of the ipi and ipi-nivo data reported in this setting?   Dr. Jason Luke: So I think this is a really interesting study because I think part of the intent is the clinical aspect of how you manage patients with cutaneous squamous cell carcinoma. For those that don't do cutaneous oncology, many of these patients have the development of lesions, which can be actually quite difficult to resect in a way that's not otherwise mutilating or cosmetically quite problematic. And that was part of the impetus for this trial where, again, they looked at either monotherapy PD-1 or a PD-1 plus CTLA-4, and they saw great success. As was predicted based on the other data that you alluded to, response rates are more than 50% near 60%, with actually a substantial number of patients on the trial actually refusing to have surgery after they received their neoadjuvant therapy because they were so certain that they had had a good outcome.    So I think these data are quite reassuring in the context of all of this emerging data around cutaneous squamous cell carcinoma. We'll talk about this NEO-CESQ trial in just a second, but I think it really is emerging to be the standard of care very soon for the use of perioperative PD-1 for cutaneous squamous cell.   Dr. Diwakar Davar: What do you feel about the dose and schedule of checkpoint inhibitor therapy used here? So the dose of ipilimumab used was ipi-1 and not ipi-3, and they waited 4 weeks. So when patients only got two cycles of Q2 weekly nivo, and one cycle of ipilimumab, do you think the responses would have been deeper if they'd waited longer?   Dr. Jason Luke: I think it is possible that they might have been deeper, although I'm not totally sure about that. One of the other abstracts we're not directly mentioning here was a study in Merkel cell carcinoma which suggested that in fact, adding ipi and that also highly immuno-oncology-responsive tumor type did not add to the response rate. So I'm not totally sure about that. I think rather what would be most interesting here is sort of the sort of next generation of biomarker work.    As part of their presentation, the MATISSE trial team showed gene expression profiling that really strongly identified which patients were going to do well on the trial. And I think that's probably eventually going to be how we need to think about this. There are patients in the neoadjuvant setting who are going to do really well with anti-PD-1 alone. And then for those who aren't, that's where we probably really need to think about do we need combos, how long to give the treatment, etc. And I think we're really only on the cusp in the beginning of this, which is exciting as we think about moving into the future.    Dr. Diwakar Davar: Certainly, many combinations are being evaluated in this space and we are very excited for the data that it's about to hopefully come in the next couple of months to years.    So the NEO-CESQ – it's quite a puzzle as to how to pronounce this acronym – and this evaluated cemiplimab in the high-risk setting. So it's worthwhile noting that Dr. Gross's first trial looked at high-risk stage 2, 3, and 4 disease. So the context of cutaneous squamous cell carcinoma that's node-positive disease and distant metastatic disease that is in one location or patients with node-positive disease invention. And his multi-institutional cemiplimab trial of four cycles evaluated included patients with stage 2, 3, and 4 disease.    So here in a study just in stage 3 and 4 diseases, Dr. Ascierto reported the results of 2 cycles of cemiplimab and importantly, these patients had both the neoadjuvant and the adjuvant portion of cemiplimab. So, Jason, you mentioned earlier that one of the key aspects that we start thinking about neoadjuvant therapy is exactly how much do you need. Do you need both the pre-surgical therapy and the post-surgical therapy? Is the presurgical therapy enough? After all, neoadjuvant response equals cure. How much benefit are you getting from post-surgical portions? So what do you make of the results that they've seen here and what is the impact? How do you think we'll be disentangling the impact of the neoadjuvant and the adjuvant portion of the immunotherapy upon response and survival?    Dr. Jason Luke: So just to leverage those comments, I think these data are reassuring because in this higher-risk group of patients, they saw excellent outcomes very similar to what Gross et al had previously reported. So that's good. To your question about how we are going to disentangle this adjuvant versus non-adjuvant question, there's a trial in melanoma called the NADINA trial which is ongoing now in which the use of the adjuvant therapy is actually risk-adapted. So after patients have an initial neoadjuvant treatment they're evaluated, and if they have had a pathologic complete response, they're actually going to stop that treatment and they're not going to give the neoadjuvant therapy. And so I think obviously it's a slightly different disease, but those kinds of data, I think, will be very meaningful to help us sort this out.    And I'm not sure whether or not in cutaneous squamous we would need a different trial than in melanoma, although I think in a different tumor, maybe like, say, lung cancer, you probably would need a dedicated study to try to look at that because I think just the responsiveness to checkpoint blockade is going to vary quite a bit once you get outside of cutaneous oncology. But to summarize, reassuring that a similar pathologic response rate, and I think this question of adjuvant or nonadjuvant, I think that's the next question we've got to answer in the field.    Dr. Diwakar Davar: We have now come to the end of our back-and-forth discussion on these very, very exciting abstracts. So Jason, thank you for highlighting these advances and for engaging in a robust discussion.    Dr. Jason Luke: Thanks for having me.    Dr. Diwakar Davar: And thank you to our listeners today for taking the time to listen to this podcast. You will find the links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear in the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcast.    Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  Follow today's speakers:   Dr. Diwakar Davar   @diwakardavar   Dr. Jason Luke   @jasonlukemd      Follow ASCO on social media:    @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn      Disclosures:      Dr. Diwakar Davar:     Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences    Consulting or Advisory Role: Instil Bio, Vedanta Biosciences    Consulting or Advisory Role (Immediate family member): Shionogi    Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences    Research Funding (Inst.): Zucero Therapeutics    Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy    Dr. Jason Luke:      Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical , Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX    Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine    Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure    Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)    Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio        

Hey there Cassettes, and happy summer vacation! This week we wrapped up part one of season 8 here at the BCD with a briefcase about the 2001 Disney film, Recess: School's Out! Our show has gone through some changes this season, and we haven't been able to give you episodes as often as we'd like. But, we're taking a short break and we hope to come back better than ever! Thank you so much for all your support!

Did you know the average bare-metal physical security hardware system uses only 60% of available CPU resources and 45% of memory? As more industries transform their video camera systems into intelligent solutions capable of providing valuable insights, they could be underutilizing their resources. Fortunately, by adopting a virtual architecture, businesses can optimize their system resources by consolidating them within a virtual environment. This approach not only maximizes resource utilization but also reduces reliance on physical hardware, sometimes even by up to 50%. In this episode, we delve into the profound impact of virtualization on the video analytics field. We explore strategies to overcome implementation challenges and discuss why businesses should seriously consider making this transition sooner rather than later. Join us as we explore these ideas with: Darren Giacomini, Director of Business Development, BCD Christina Cardoza, Editorial Director, insight.tech Darren answers our questions about The evolution of physical security systems Challenges with obtaining valuable video data analytics The role of virtualization in providing valuable insights How to successfully make the move toward virtualization Lessons learned from others in the industry Partnerships backing the move toward virtualization The future of virtualization for businesses Related Content For the latest innovations from BCD, follow them on Twitter at @BCDvideo and on LinkedIn.

https://divernet.com/scuba-news/freediving/british-freediver-breaks-15-year-national-record/https://divernet.com/scuba-news/wrecks/ship-held-in-connection-with-british-war-grave-looting/https://divernet.com/scuba-news/health-safety/wrong-place-wrong-time-diver-whose-head-was-in-crocs-jaws/https://divernet.com/photography/photographers/ocean-sentinels-form-new-gbr-dive-trail/https://www.scubadivermag.com/phone-survives-5-months-underwater-in-a-sealife-housing/https://www.scubadivermag.com/ddrc-healthcare-launches-lung-survey/https://uk.apeksdiving.com/en/dive/bcds/exotec-s---dive-bcd-BT142.htmlScubapro SCUBAPRO is the world's most iconic brand of dive equipment for those whose passion is under water. Websitehttps://www.scubadivermag.comInstagramhttps://www.instagram.com/scubadivermagazine/Facebookhttps://www.facebook.com/scubadivermag/YouTubehttps://www.youtube.com/c/ScubaDiverMagazine/Scuba Diver Magazinescubadivermag.com/subscriptions

Are you a person that flies by the seat of your pants? Do you fly like Maverick in Top Gun where your instincts dominate? This is absolutely cool in the movies, but it kills pilots in real life and the ones that kills are the amateurs and the experienced professionals. It's called spatial disorientation. First, let me give you a definition.Spatial disorientation – It's the inability of a person to determine his true body position, motion, and altitude relative to the Earth or his surroundings. Both airplane pilots and underwater divers encounter this phenomenon. Teresa and I earned our PADI Open Water certifications in July 2001, which allowed us to dive 60 feet. PADI stands for Professional Association of Diving Instructors. We then went on an epic adventure in the Fiji Islands to vacation and SCUBA dive the Great Barrier Reef. This is one of the best diving spots on the planet. It was a life-changing experience. We saw incredible tropical fish, puffers, tiger sharks, all kinds of coral, and amazing sea life and creatures. You gain a respect for what's underwater. When a human becomes like a fish, you better respect that environment. We were trained to follow our instruments down to 60 feet, which basically included a buoyancy control device (a BCD), a regulator, a suit, and oxygen tank depth gauge. I learned to trust my depth gauge. It was crucial to follow my instruments as well as use my eyes and ears to decide to go up or down while diving. There's charts you follow so you don't get the bends. There are many more components. I'm just trying to keep it simple. I can remember a few times where I swam up, thinking I was going down. Even worse, I swam down, thinking I was going up. Thankfully, I learned to trust my instruments to correct my positioning under the water. When you are that deep, it is really hard to tell which way is up or down. It's scary, but it's true. I'm so thankful that I was taught to trust my instruments.Here's another example of spatial disorientation. My friend Royce Repka, owner of Double R Flight Academy out of Perkasie, Pennsylvania jumped on a phone call with me to explain the phenomenon of spatial disorientation from the flight instructor point of view. He's been doing this for nearly a decade, and he knows his stuff. So I'll paraphrase."Ken, think of it like this. Humans spend 99.99% of their time on the ground. It seems flat, right!? In reality, we are standing on a curved surface that is spinning and rotating. We can see the ground and we can visually see the horizon. The ground is down and the sky is up. That's obvious. You have reference points."I understood this from personal experience dealing with Lyme disease and vertigo. A physical therapist, who is trained in the inner ear for vertigo taught me that our eyes see the ground and the horizon and it communicates with our inner ear to balance your body in relation to the level of the earth. People with vertigo suffer dizziness because their inner ears are out of whack. Others can even get crystals that dangle in the inner ear. It can trick the senses to give you vertigo even when you're standing straight. And there are techniques that physical therapists can do to remove those crystals.Read the rest of this article at the Smart Cleaning School website

We couldn't be more excited to kick off #aapiheritagemonth by sharing this episode featuring our podcast inspo and friend - Hana from Bulgogi Podcast!!! From our very first hang out, we realized the different stages of dating we were each in. In this episode, we kick off single girl summer by swapping past dating stories, revealing: the behind the scenes dating process after a match is made how to initiate the first moves with a boy whether a first kiss or hand holding is more intimate and more tips and tricks to navigate the first few dates. 0:00 Introducing Hana!!! 4:25 He asked for my number at BCD?!?!? + Forming a task force to perform a "screening process" for a date ;) 11:50 Things you MUST do before a first date 16:00 Do you "nickname" the boy on the first few dates and why we do it? 18:20 Hana's "scrapbook" of dates and meeting people that reveal your own strengths to you 27:00 Do you like the attention or do you actually like him? 31:30 Kicking off our single girl summer and how to initiate the first moves 35:10 Dating ick stories 43:30 What feels more intimate: kissing or hand holding? 51:10 Can you tell if you like someone based on a first kiss? + and more!!!!! ♥ Hosts Emily & Janice   ♥ Follow us ⁠Instagram⁠ ⁠TikTok⁠  ♥ Listen ⁠All platforms⁠  ♥ Graphics Special effects, graphic design and branding by ⁠Devin Bennett⁠  ♥ Music Jingle produced by ⁠Barry Tan

In this episode of the WE Blended and Blessed Podcast, Wayne & Erica (WE) discuss the challenges of bringing custody cases to court with the Honorable Judge Calvin Johnson and Dr. Deidre D. Hayes, DSW, BCD, LCSW-BACS. We discuss the impacts of introducing the justice system in custody cases, legal fees, and the affects to children and parents alike.#weblendedandblessed #blendedfamily #podcast #custodyPlease be sure to like, follow, or leave us a comment on our Instagram page @weblendedandblessedpodcast | Facebook: WE Blended & Blessed Podcast | TikTok: @weblended&blessed | Twitter: @webandbpod | email: weblendedandblessedpodcast@gmail.com

Hello, Cassettes! Welcome back to another (brief) case from the BCD! We will be resuming our regular episodes very soon, but until then, it's time for our annual Oscars episode!! Did your favorites win last night?  Twitter: @blackcasediary  Instagram: @blackcasediariespodcast Website: blackcasediaries.com

飛碟聯播網《飛碟早餐 唐湘龍時間》2023.03.03 週五體育單元 悍創運動行銷公司創辦人 張運智 《第5屆世界棒球經典賽即將開打！》 ◎內容簡介 2023年第五屆世界棒球經典賽（World Baseball Classic 2023），將於2023年3月8日至12日舉行，第四屆參賽隊伍16隊直接從會內賽出發，另有4名額從資格賽產生。會內賽將分為分組賽以及淘汰賽，分組賽階段20支隊伍分成A、B、C、D，4組於4城市進行單循環賽，取前2名晉級淘汰賽。A、B組前2名將於東京巨蛋決定誰能揮軍美國，C、D組前2名則直接在邁阿密舉行淘汰賽。四強賽與冠軍賽一樣都會在邁阿密的LoanDepot Park舉行。 中華隊熱身賽賽程 3月5日（日） 11：00 巴拿馬 vs 統一7-ELEVEn獅 @斗六棒球場 12：00 荷蘭 vs 富邦悍將 @洲際棒球場 15：00 義大利 vs 味全龍 @斗六棒球場 19：00 古巴 vs 樂天桃猿 @斗六棒球場 19：00 中華隊 vs 中信兄弟 @洲際棒球場 3月6日（一） 11：00 義大利 vs 統一7-ELEVEn獅 @斗六棒球場 12：00 古巴 vs 中信兄弟 @洲際棒球場 15：00 荷蘭 vs 台鋼雄鷹 @斗六棒球場 19：00 巴拿馬 vs 味全龍 @斗六棒球場 19：00 中華隊 vs 富邦悍將 @洲際棒球場 【2023 WBC分組】 A組：中華（14）、荷蘭（4）、古巴（7）、義大利（12）、巴拿馬（資格賽晉級） B組：日本（3）、韓國（10）、澳洲（9）、中國（16）、捷克（資格賽晉級） C組：美國（1）、墨西哥（13）、哥倫比亞（11）、加拿大（15）、英國（資格賽晉級） D組：波多黎各（2）、委內瑞拉（8）、多明尼加（5）、以色列（6）、尼加拉瓜（資格賽晉級） ▶ 《飛碟早餐》FB粉絲團 https://www.facebook.com/ufobreakfast/ ▶ 飛碟聯播網FB粉絲團 https://www.facebook.com/ufonetwork921/ ▶ 網路線上收聽 http://www.uforadio.com.tw/stream/stream.html ▶ 飛碟APP，讓你收聽零距離 IOS：https://reurl.cc/3jYQMV Android：https://reurl.cc/5GpNbR ▶ 飛碟Podcast SoundOn : https://bit.ly/30Ia8Ti Apple Podcasts : https://apple.co/3jFpP6x Spotify : https://spoti.fi/2CPzneD Google 播客：https://bit.ly/3gCTb3G KKBOX：https://reurl.cc/MZR0K4

In this episode, we will be discussing the critical role of social workers in public health and disaster response. We will hear from CDR Stephanie Felder, PhD, LCSW, CEM, CAC-II, BCD, ACTTP who is an expert in the field. She will share her experiences and insights on her role and how social workers can play a crucial role in addressing health and disaster-related challenges. ____________________________________ Success in Clinical Social Work Webinar reserve your spot now for this LIVE virtual event on February 21, 2023. Tap Here to Subscribe to the Social Workers, Rise! Email Resource List ____________________________________ Thank you to our SPONSORS RISE Directory - A national directory of Clinical Supervisors who are looking to help the next generation of Clinical Social Workers GROW. Therapist Development Center (TDC) Homepage TDC Continuing Education Courses On The Edge of Life: An Introduction to Treating Suicidality  Use the code SWRISE10 at checkout to receive 10% off

Hey Cassettes, and welcome back to another ranking episode of the BCD! This week, we decided to listen to a massive list of Cartoon Network theme songs and pick our top 5 favorites. What's your favorite Cartoon Network theme song?  Show notes and sources are available here: https://www.blackcasediaries.com/ Thanks for listening! 

Hi-ho, Cassettes! It's the BCD here and we're excited to share with you the story behind Jim Henson's beloved Christmas special: Emmet Otter's Jug-Band Christmas!  You can find show notes and sources here: https://www.blackcasediaries.com/ Thanks for listening!

Ho ho ho, Cassettes! We're BACK! Thank you for joining us as we embark on season 8 of the BCD. This week we started our month-long Christmas celebration with a deep dive into A Christmas Story (1983)! Come laugh with us, won't you?  Show notes and sources here: https://www.blackcasediaries.com/

We are all leaders in some area of our lives whether it's in the office or at home. How do we know if we are good leaders or the traits that could help maximize our strengths? Listen to this conversation to remove the limiting beliefs and define leadership for you. If you have any questions about this episode or want to get some of the resources we mentioned, head over to LesleyLogan.co/podcast. If you have any comments or questions about the Be It pod shoot us a message at beit@lesleylogan.co . And as always, if you're enjoying the show please share it with someone who you think would enjoy it as well. It is your continued support that will help us continue to help others. Thank you so much! Never miss another show by subscribing at LesleyLogan.co/subscribe.In this episode you will learn about:What does it mean to be a good leader? How you learn to be kind to yourself How to properly understand and utilize your Strength Finders resultsDefine your limiting beliefLearn to master your mindset and your heart set Episode References/Links:Strength Finder 2.0Kevin Kepple IGUnlock Your Freedom PodcastKepple Coaching Website  If you enjoyed this episode, make sure and give us a five star rating and leave us a review on iTunes, Podcast Addict, Podchaser or Castbox.Be It Till You See It Podcast SurveyUse this link to get your Toe Sox!ResourcesWatch the Be It Till You See It podcast on YouTube!Lesley Logan websiteBe It Till You See It PodcastOnline Pilates Classes by Lesley LoganOnline Pilates Classes by Lesley Logan on YouTubeProfitable PilatesSocial MediaInstagramFacebookLinkedInEpisode Transcript:Lesley Logan  How do you say your last name Kepple?Kevin Kepple  Correct. I do that too.Lesley Logan  I swear I'm a professional.Kevin Kepple  I do that too. Like, "Oh wait." ....Lesley Logan  All right. So I'm like I'm just gonna tell you right now it was, this podcast is a party. And also our guests, Kevin Kepple has so many lines, so many words, so many nuggets, so many gems that I'm that I don't even know how we're gonna quote them all because there's so many good ones that I cannot wait for you to hear in your ears. So if you are listening to this while drafted an email, may I suggest that you hit pause on that email. And you take some time walking with this podcast or grab a notebook because Kevin Kepple is someone who like all of us, started off at one thing, is doing another thing and found, found the best way to be the person that he is. And y'all I'm going to tell you right now, one of those nuggets is about being more not doing more. Oh my gosh, I cannot wait to hear how you be more instead of do more after hearing his words, this podcast, our conversation. I have so much gratitude for Kevin and hope you enjoy this. Let me know how you take the this podcast away, what your test takeaways are. If you answer those questions he gave you at the end they're so great, they're so brilliant. In fact, they're questions you can like literally write down somewhere copy and paste every time you need them. They're freaking great. So without further ado, here is Kevin Kepple.Hey, Be It listeners. Okay, I'm super excited because this man who are you're about to hear is really awesome. Talk about being it till you see it, they have so many examples and that they truly are walking the talk. And so I have Kevin Kepple here and I'm really excited to share with you his amazingness. So Kevin, who are you? What do you do these days?Kevin Kepple  What? What's up, Lesley? As you said, Kevin Kepple, you know, I get to work with lots of different types of leaders, usually executives, or business owners, and really help them create more access to happiness and aliveness. And, you know, if we want more, it's not about doing more, being more as the goal and just really helping them be more of the natural genius that they have. And stepping into that so they can serve at really high levels and their own unique expression of amazing.Lesley Logan  Okay, so many things to love about that. And of course, you know, I love the being more like, I mean, you're at the right podcast for that. But how did you before we get into being more? How did you get into this? Like, was this something that you started out right away? Or how did you start to see that, like, leaders out there needed to stop doing so much and being more than they were doing?Kevin Kepple  Yeah, I mean, I woke up one day, when I was a kid, I knew exactly what I wanted to do for the rest of my life. And it was so easy, and (Lesley: Who are your parents?) everything worked out perfectly. No, I wish. No, no that isn't true. You know, I, like a lot of people have had you know different jobs, I went to college, got out of college, and happily ever after. Right. And I got a job that I was good at, but then have a lot of joy in and expose lots of different types of leaders, you know, they're teachers, sports, corporate career, other jobs, and there's good leaders, and there's bad leaders. And I just remember being really frustrated when in one day, when I had a, the VP of the company was screaming at me and profanities. And I just feel like there's got to be a better way to lead people. And so I've got a lot of contrast of what not to be, which is great, right? Really grateful for that. And, he's doing the best he could with what he had. I worked in different types of professional sales roles for years. And I worked at enterprise software sales for a number of years and worked in financial services as well. And I was winning the trips and all that good stuff. And I got promoted, because that's what happens when you do well at a job right, you get put in charge of people like that makes you a good leader, for some reason.Lesley Logan  It's true. That's exactly how it goes. They just go, "Oh, this person sells a lot. So let's put them in charge of people."Kevin Kepple  Yeah. They must know how to tell people what to do, which is not leadership, right. And I've, you know, I figured out that I really enjoyed helping people, you know, like, be more without making it feel like less, like, that's always the goal. And you don't have to win my way to win. Matter of fact, you know, you're not going to win my way because we're never going to be creative making copies of other people. And I'd love to go further faster like whatever I'm doing, I want to maximize it. And so I was working with a coach. And I remember he asked me what I liked about my job. And this dude was awesome. He was in the Secret Service for almost 30 years. And he kind of looked right through, you know. (Lesley: Yeah.) And he's like, "What do you like about your job?" And I'm like, "Well, I love this. And I love that. And da da da." He's like, "Hang on, hang on." He's like, "Stop." He's like, "Dude, I don't think you'd like your job. You keep saying I love." He's like, "You're not even looking at me. Your body language is all wrong, your tone is all off." He's like, "Just one thing you like." And I had a lot of trouble getting there. And it's really like helping people, you know, the people that were on my team, I caught up in them just find the best, most authentic expression of themselves. And I'm like, okay, but that's such a small part of what I get to do, you know, like, and, like I really knew I was in the wrong place. I was on some trip, and there was like a teaching part we had to go to, and they were talking about tax codes. And I was, like, 30 seconds, I was ready to get out of there. I'm like, I think I'm really gonna slam my hand in the car door, then sit here and listen to this, because at least I have something to do think about ...Feel like I won a trip. And I've had to listen to tax codes, great.But I knew I was in trouble because I looked around and people were really excited. Like, everybody's like, engaged and into this and I was like, "Okay, there's definitely been some sort of a mixup." I'm not supposed to be here. And a coach is like, "Dude, what do you want to do?" I was like, "I want to help people." He's like, "Everybody wants to help people." And some form, he's like, "How do you want to help people?" And I had no idea and now he's like, dude, long story short, he's like, "I think you'd be a great coach." And then the limiting beliefs kick in and all the fear, right? I'm like, well, I don't really struggle because like, now if you throw a rock, you hit five coaches, right? Like they're everywhere. And you know, this was years and years ago, and ...Lesley Logan  Now if you throw a pebble, you'll hit seven coaches. (Lesley and Kevin laughs)Kevin Kepple  Yeah. Follow into. But, you know I really simple I just made it the intention, like, "Hey, you know, like, I want to find something that supports this dream." And there's a little bit more to it, but fairly simple. And I looked on LinkedIn, which I didn't do frequently, and I saw an opportunity with this international multibillion dollar company that's based in Dallas where I live, and for a national sales and leadership coach, and I'm like, "Hey, that looks cool." And so I took that job. And the only requirement was I had to move to Chicago. And I was really smart about it, though. I was like, oh, wait till after winter, and I moved in May. I didn't know Chicago does extra winter. So it (Lesley: Yeah.) was still snowing at May. It was really great. I worked for them for about three years. I got to really coach and train people all day, every day and work with powerful people. And I really learned how to do it, I do it at a high level and stepped over started my own thing years ago. And it's all good, now.Lesley Logan  Yeah, I mean, I'm sure there's all it's got its own journey because working for yourself, it's its own thing to learn. But what I what I find, which I like love, like, "I want to work myself." And like it is actually as hard as working for someone else is just a different kind. But I what I love about this is like you, you challenge yourself to like put yourself in a position to be for someone to see you and to see like, what, like maybe what you weren't seeing because I think a lot of us talk ourselves into the jobs we're in, or like I'm just I'm really good at this and like keep getting promoted. I I literally had to quit a job. So they would stop promoting me because I like if they promote me one more time. I'm gonna say yes. I can't stop. I can't stop. So I think like, you know, I think it's I wish I had as a secret service person going you don't actually do you know, you don't like this job? Did anyone ever tell you? So when you sort of go into leadership coaching, what is it that you see? Because like, there's a lot of people in leadership roles who actually want to be in these roles. And there's a struggle because they want to they think doing more is the thing. So what do you think makes a good leader? And what is it different for each person? Or what what is this, what is something like a sign that someone should take like, "Oh, I'm a good leader."Kevin Kepple  Is anybody following you? Right. Like, because leadership's not a position like you can be the President of a company and not be a leader, you know, leaders like an action really. And, you know, leadership is different than management, management is telling people what to do. A powerful leader is going to inspire and empower people and inspire me, you stimulate me to action, you power me, you give me knowledge and tools of how to do it, you know, but winning with my gifts, not winning your way. And I think that just no, are you telling people or are you asking? It's probably the simplest way to know if you're exhibiting leadership or just simply management because you're telling me what to do this not leadership has told me what to do.Lesley Logan  That's so fas... that's the best description I've ever heard. I'm like thinking of every single, like, my brain just went to every single boss I'd ever. (Lesley laughs) And like, um, and it's so cool, because that means you don't have to get a promotion at work to be a leader in your in your role.Kevin Kepple  Yeah, and dude, anybody can be a leader, like, you know, like, god bless moms, like we wouldn't be here without moms, like one of the hardest leadership roles in the world. And you know, you're like, I went to a four year olds birthday party this weekend. I was like, man, it's like, they're all drunk and on drugs, like they were all over the place. And that Spiderman there and little kid walks up to Spiderman. And he goes, "My favorite superheroes is Batman." I was like, "Your, that's leadership right there, buddy. Speaking up for what you want." You know, but I just think it's, it's a behavior. It's not a position. And, you know, like somebody's watching you, period. And there's like, certain leadership traits for sure, you know, that you can pay attention to an increase, but really, it's just about, you know, how are you showing up?Lesley Logan  And so when you were stepping into this new role, was that an easy thing for you to figure out? Was that something natural for you? Or did you actually like have to, I don't know, like, get lessons on on and leading versus managing.Kevin Kepple  I think I'd spent so much time thinking about it, and just always really gravitated towards leadership positions, whether it was played baseball and hockey for a long time. And, you know, it's not always I don't need to be the one in charge. But, you know, quite often, you know, leaders are going to emerge just because of the behaviors they're exhibiting, etc, etc. I love to read, and I love to just study people who are successful and see what they're doing and how I can use that to help people you know, through my own style, and had some really great, so there was, of course, a learning curve, and they're always learning, right, like, I don't know, is the most powerful phrase I ever learned how to say it took me three decades, but I finally got there and learned how to mean it. But just watching other people, you know, like, what do they do well? Like, what are they doing that I shouldn't be doing? You know, that contrast is so powerful too. And just being really, I think just being really kind as opposed to right was one of the best things I learned how to do like kind of myself as opposed to right about what I was doing wrong or kind of other people and just learning to not need to be a certain way to be okay. I think that allowed me to evolve pretty quickly.Lesley Logan  Yeah, that kindness to ourselves, um, That's not something, I feel like, I feel like maybe going back to those little kids at a birthday party, maybe there's a natural kindness that they have. But somehow, at some point, we stopped getting, stopped being so kind to ourselves and we start putting others maybe I don't know, I've been out of the corporate world so long but putting other people and being nice to them versus being kind to them, but nice to them at least versus ourselves first and I wonder, I mean, you really can't be a leader if you're not being kind yourself because you're gonna make mistakes. So how did how do you learn to be kind to you?Kevin Kepple  I think it's, you know, the great skill, right? Choosing love over fear. It's like, you know, if I'm be in love, that's I'm gonna attract more love into my life, or that's like unconditional love. Not romantic, necessarily. But unconditional love. It's like not because like, everything we've ever done was motivated by fear, love, if you look at every decision you've ever taken, I guarantee you, you can boil it down to one of those two and fear can wear hats, right? Guilt, anger, apathy, shame, pride, all those are fear based, right? Forceful behavior. And love is love and unconditional love means like, I love me, no matter what happens. I love you, no matter what you do. Like, I don't have to like you to love you. Right. And that's, that's why we get married. So we can practice that with our in laws, right? I don't know how to ... (Lesley laughs) Yeah. That's a joke. (Lesley: One of my in laws listens to this podcast.) We're not talking about you.Lesley Logan  We're not talking about you. (Kevin: You're cool.) Other people's in laws, though, those ones. (Kevin: Yeah, on TV.) That is, well, thank you for sharing that, because what a great example of like, of a kind of love that we are practicing in our lives. Like, I think some people may I know some of my listener that can be so hard on themselves, they may not realize that they're actually practicing unconditional love in different ways. And, and there's a difference between liking someone and having love for them. And so giving ourselves credit for where we are in practice, and, and, you know, an honoring that because when you can see that you are in practice, and you can practice again, and you can show up another day. So when you work with leaders, like what is your what is your first thing? Do you observe them in practice? Do you like be a fly on the wall in their office? Or like, what's your process?Kevin Kepple  Here's what's wrong with you. (Lesley and Kevin laughs) And we're gonna need more than an hour, you know. No ...Lesley Logan  Just my assessment.Kevin Kepple  That's fun. That would be fun and really hard at the same time. But, the first was a start. So have a certified by Gallup with the Strength Finders tool, or ...Lesley Logan  Oh, we're gonna talk about that, that's my freakin favorite tool ever. Keep going. Keep going.Kevin Kepple  Yeah. It's so phenomenal like that right there. I mean, it's a cheat sheet into your elite levels. And it's not a complete portrait of your character. It's like, "Hey, here's what you do really well. But even maybe more important, here's what it looks like when you give all your power away." And like, what a cool gift, it's a cheat sheet into your, you know, extremely high levels of satisfaction and performance, whatever. And, like, we all know that everybody's different, right? But we always look, I'm gonna look at the world through her eyes, and you'd look at the world through her eyes as yourself, that's not gonna do you a lot of good. But if I can look at the world through your, like natural patterns of behavior and high energy, and you know, exceptional performance, like, that's really cool. And, you know, I think probably the greatest gift for Strength Finders was, if I had permission to be me, like I told you, I was working in finance, and I hated Excel. I hated it tax codes. Like, "I think there's something wrong with me." Like, "No, dude, you're just not built to like, that kind of thing." And that's totally cool. So I start with that, because, I mean, just one conversation with somebody, you can shift people so fast. You know, like, if I tell you, Lesley this, if I tell you, Lesley that, you may hear it, but if you see it differently from within, right, cite from within insight, like that's how you create lasting change. And, like, it's such a cool thing, because at this juncture, I've worked with 1000s of people with the Strength Finders assessment. And it's always like, so onpoint, people are like, sometimes when people get their results, like, "Well, this just isn't right." Like, it's usually because they don't understand it. And once I explain it, like, "Okay, that is me." And you know, we think we want or we don't have but then when you start looking at the things that aren't natural for people like, like, "Do you want to do that?" Like, you know, like, woo - winning others over is a strength, right? A lot of people who don't have it, like I wish I had woo. I was like, I have like an incessant need to talk to everyone shake every hand in the room, "Do you want to go talk to everybody in the room?" Like, "Oh." But people with woo like, "Yes," you know, and like, that's cool, man. There's nothing wrong with that. If you're built that way.Lesley Logan  I'm laughing because I'm 100% introvert and woo is in my top five. And it's exhausting because it's like, I can't leave. I need to go lay down.Kevin Kepple  There's somebody over there on the other side of the warehouse, I haven't talked to you. Yeah. You guys are so good because you protect the rest of us though. (Lesley: Yeah) Because y'all can actually get energy from that. And like, it's really fascinating to watch the people with woo work, and I was I use that specifically because I know I knew that you had to have it. As soon as we got on I was like, that's woo because you made me feel really good.Lesley Logan  Well, thank you and also I think like, also our strengths if we like leaning into them a little bit. Like I knew there was a time when like, I was not winning someone over. I was like, "I'm gonna stick around in this relationship till I win you over." And it's like, "Oh, actually, maybe it's just not that into me." Yeah, that's a, that's a story for another day, everyone. But here's what's here, you're gonna get a kick out of this. This is this is how much Strength Finders like matters to my husband and I. So we were on a first date that he didn't know he was on. And he just told me, he was going through a divorce. And I was like, "Okay, that's this person's not really going to be dateable." But then we started talking about, like, the businesses we ran and all this stuff. And he had a band. And he worked for a startup. And I had written a book. And he mentioned he's like, "Oh, have you heard of Strength Finders, 2.0." And I was like, "What are your top five?" And he pulled out his top five, I pulled up my top five, we've three that overlap different, different orders, and the top five, but three out of the five. And then he was like, "Do want to get out of here?" And so that was like, that was our way of getting together. (Lesley and Kevin laughs) But it is those in your you're correct in how it really makes you understand yourself. And like who you are so much better because I could not understand why there were certain things that would just like, I would go all end with light me up. And other things that I'm like this like, but like one of my top five is significance. So it's like, it has to matter. (Kevin: Yeah) It has to be important. And then I also have activator or positivity, woo and connector. And so it's like, those are I don't know which order they're in. But like, I feel like significant significance was in the top three and activator and connector on the top one up there. But like, I just I was like, oh, this is why like, I literally meet someone and I have to connect them over here. And I do like, I really love doing that. And my husband has told the story on the pod before. So if you've heard it before, I want your hearing again, but Kevin hasn't. He was trying to figure out how he like, why in the band he was the one making sure they all got paid and making sure all these things and he couldn't really figure out like, what, what like, made him up. And when he did that. He's like, "Oh, this is why I'm the person who does this at work. And this is why I do this." And it really helped him understand that he had transferable skills, not just in a band, but also in a business. And so now he's the CEO of our companies. But like how cool that a test like that could actually go oh, this is why you're so like, this is what you can do in another company. You don't have to just go while I'm in a band, you know.Kevin Kepple  Yeah, but that's such a great point you know, like, we're all different. We know that. But do we actually own that? And like, I have an older brother, he's two years older than me, but like, I always joke that like, "Dude you're born like 70 years old." He's like, "Always been like very wise and responsible. And just like, cartoons are stupid, that would never happen." Like, I'm like, "Dude, we're like four years old man ..." (Lesley laughs) And he's so serious. And I used to compare myself to him, right? The comparison game, we'd like to look at other people so we can feel inferior or superior, right? The worst game anybody ever plays? And I'm like, well, I can't do the things he can do because it's number one strengths, deliberative, it means he's slow. He's methodical. Assess every risk before I even start. And to you and I who have activator really high. We're like, dude, I got bored and quit listening. I just want to jump off the cliff, build the wings on the way down, right, whatever that looks like. (Lesley: Yes.) Don't give me instructions. Like that slows me down. I have to come back and ask for him later. But just don't give it to me up front. Just let me get started because ready, fire, aim is such an effective strategy for us. (Lesley: Yeah.) Just we're different ...Lesley Logan  Yeah. Oh, I hope my whole entire team listen to this because they I'm like, "I have this idea." And then they're like doing the whole project management. And I'm like, "I'm already, I'm already 17 steps ahead." I've already asked them. They said yes, these people are going to do this. And they're like, "Wait, you have moved to the process." And I'm like, "No, because I want to know quickly if this plane is gonna fly or not." Like, I don't want to build it (Kevin: Exactly.) and then it doesn't work.Kevin Kepple  ... with activator, what we get is that WTF look a lot because we start so far ahead of starting point is like, if somebody asks you to explain the alphabet, you're like, yeah, it ends with y and z. Like, wait, what? And it confuses people. And it's not like smart or dumb. It's just like, we're ready to get to the end. And we can begin with the end of mine really easily. And it's so powerful and so good to have people around you that can do the processes and support you and help you find the things that oh yeah, maybe we should get insurance but ...Lesley Logan  Well, you know what is also great about them because they are listening to us. Sometimes the idea is really fucking awesome. And it goes great. And then we need to fly again. So it's really nice when they're like okay, here we can just like repeat, rinse and repeat. (Kevin: Yeah.) Oh, this is so so okay, so people you have people do this and then you have them have them understand their strengths better. And, and then in turn, hopefully that helps them take these next steps as a leader just owning who they are as opposed to trying to be something that they're not in their role.Kevin Kepple  Yeah, absolutely. And really just helping, you know them understand like it's one of the cool things about strings like your natural sources of energy. And energies can be in different, right? Like it's power, it's our natural power. But, you know, gravity is super powerful, you know, you and I don't float away to the moon or whatever, right, thanks to gravity. But if we go up to the top of my house and jump off, we go crashing into the ground, right? It's not malicious, it's just going the way I direct it. So with my strings, I need to make sure they're pointed the way I want, you know, like, significant, you mentioned that one, I have that one fairly high too. And that's a really great strength, because it's about my make an impact, make an impact on other people, make an impact in the world, make an impact on ourselves. And that's the balcony. Right. The the good version, you know, that, that negative space on that the basement, if you will, you know, the basements like when I make things really important that aren't that important, right? And so, you know, maybe even making it all about me, right? The the the monster comes out, and then like, you know, just pushes people away.Lesley Logan  I feel like I'm getting a therapy session, everyone, because I'm like, oh, I do, do that. That is a bet. That is not so great.Kevin Kepple  But what's the wild with that assessment? Okay, so, Gallup, I love you guys. They're the ones who created Strength Finders, but like your marketing, people need to have a talk. I mean, you'd have a little heart to heart here.Same with their website.Yeah, their website, they just redid it a couple of years ago. I'm like, somehow it went regressed. But they rebranded Strength Finders to Clifton Strengths in the middle of the pandemic, because that's what you do when you have an assessment. Somebody's taken 30 plus million times you change the name to something even more obscure that nobody understands. Don Clifton was the guy who created Strength Finders, like thank you, Don in heaven. But you know Clifton Strengths assessment doesn't really help me understand what it is. And now it makes it harder to find for people. So StrengthsFinder is CliftonStrengths, same exact assessment. And they package it where you can buy the top five or all 34. (Lesley: Yeah.) And so like when I went to Gallup years ago, "They're like you have any questions?" I have lots of questions. And I'm like, "Why is competition not higher for me? I feel like I'm the best at Strength Finders." And they're like, "Yeah, it's number six." I'm like, "But it's not my top five." And so here's how you read the report just for you guys. Here's how you find your dominant strengths, your dominant strengths go all the way down to 10 11 12 or 13. Somewhere in those three numbers, like out of the again, 33 like plus million times I've done this. So you read when you read the top 10 in your head, you read the definition, it should sound like this. Yeah, that's pretty much always me. Either after 10, after 11, after 12 or 13, it stops and it stops. And it sounds like this, instead of being pretty much always meets. Well that sometimes me but not always. So you just draw a line right there. Everything above that line, those are your dominant strings. So even like 12 or 13 can be as strong as one sometimes. And just because of the way they package it though a lot of people don't understand that and myself included in the past. So ...Lesley Logan  That's interesting. I did the top 34 because I wanted to find a new assistant. And I didn't want to find another me because I knew I would like love someone else who was like me. I would love someone I got that'd be so much fun. But I'm an ideas machine. (Kevin: Yeah ... And what about the details?) Yeah, and those no details, correct. I mean, I married someone with a detailed up I thank God, but, um, but uh, but I made sure we have everyone who like has to be on my team. We like do their Strength Finders, and they have to like make up for the bottom. There's gonna be someone who can make up for the bottom. Because otherwise it's like, where's that thing? I don't I just threw up put in this folder. I don't even know. (Kevin: I got bunch of this.) Yeah, those folders.Kevin Kepple  It's funny, but you know, it's important to understand, it's not like a complete portrait of your character. It's your natural talents is all that this shows you and at the bottom is not weaknesses. It's just released express strengths. Like harmony is number 34 for me, like doesn't mean I can't get along with anyone. Right? It just means that I move fast. So I don't always wait for everybody to see what I'm doing. I see empathy at 34 all the time. And especially if it's a woman I'm working with the last, "Was that bad?" Like did that means you're a serial killer? It's really bad. Like really? Like, no, just like, super empathetic is not the end of the world. Does it mean you don't have empathy? It just means it's not like a dominant thing for you. (Lesley: Yeah.) And it's no big deal. And you know what, like, talent is not rare. Not at all. Like, I've never seen a blank report like nope, no talent for you. Sorry. Like, what's rare is people who have developed this talent into a genius they can leverage on demand. And genius has so much less to do with genetics than it does with habits. You know, get into the habit of being your most excellent self, whatever that looks like. And that's the trick right there. So simple, but not easy.Lesley Logan  So when you learned so far, because now everyone's taking this test while they're listening to us, and they don't do that you really want to be by yourself because they had to time test. But, but when you when you kind of like got into your strength, how did you lean into them without, you know like, is there is there a way of like leaning into them more or is their way of like, okay, I'm gonna exercise this strength more honoring those because I think you know, it's easy for people to go, oh, empathy is my worst one. I'm going to make that one better. It's like how did you stay in your in your zone?Kevin Kepple  That's a great question. There's probably a very eloquent way of saying this question that I get asked like, every time we were taught this or worked with somebody it's like, and like, so the basement is like our negative behavior, like when we're making it all about us with our strengths. Like, for instance, maximizer is my number one strength. Maximizer in the balcony is like, just fascinated with elite, like, whatever, like, mastery looks like in this, whether it's a person I'm working with, like, Lesley, like your champion is, I was so excited to be on your podcast, like I listened to it before I reached out, because I want to be around somebody, I feel like a master. And like, You're definitely a master at being with people and just do what you do. And that's really attractive to a maximizer, because I wanted to just be around it, so I can show you some of that for me and help people like her or whatever. And that's obviously really healthy getting to like just elite levels. The basement on maximizer is nothing's ever good enough, right? Like, well, let me just make it a little better and a little better. And it's like, how did you even get dressed today? If it's not like absolutely amazing, you know? And so it can be very picky. And so the question that people ask, like, how do I get out of the basement, once they understand the language, right? You know, it's like our blind spot. And like, man, it's really simple. Stop making it all about you, right? Because if I'm solely focused on me, then like, that gives the ego a lot of time to jump in. And, you know, the BCD is, you know, blaming complaint and defendant and fear and worry, and all those like, behaviors that take a lot of energy, but bring us little rights is an addiction, you know, like addictions all have the one thing in common, like repetition, but no payoff. And you know, people get addicted to that stress filled negative space of worrying, Kevin included in the past. And so the really the way that you can lean more into these is understand what good looks like, but also understand what you know, the basement looks like, so that, you know, what I'm aware of, I can actually do something about, you know, what I'm unaware of, that's the dangerous stuff is unaware behaviors that are just patterns in my life that take me away from what I want. And, you know, like, I can't give what I don't have, if I don't understand my strengths, and I can't use that not at the highest level. But Gallup has a great podcast, actually, if you can find it, like, they hide it somehow. But it's, it's phenomenal. I think it's called Clifton Strengths, they just rebranded that to after seven seasons. So they, they're really crushing it. But it's awesome if you do find it, because it's like 10 minutes of one strength. And you know, just like pick one a day a week. But I mean, like with anything else, like it's so important to make new decisions, like so often people make this judgment, like, oh, this is how it is like, even if it's a good thing. And whatever you like judged as being a certain thing, like you're no longer evolving there. It's like static, right? (Lesley: Yeah.) And so like, every time I go back and read about maximizer, I learned something new. Even though I've worked with this tool for years. It's still a new version of me. So I need to make new decisions, right? (Lesley: Yeah.) What, what is the next level of this look like?Lesley Logan  Oh, my God, I now have a new podcast. I'm gonna listen to it and be obsessed. But I also think that I've never heard of the terminology like the balcony in the basement. And I kind of love this because Brad's going to listen to this because we'll do a recap on you. We talk about you on air ... You have to listen to it. But like, now I can just go, "I'm in the basement. Leave me alone. I'm in the basement. I need to get out."Kevin Kepple  Sometimes we go into the basement, too.Lesley Logan  I feel that. I feel that. As an activator, I felt like that's really ... Oh my gosh. So this is I think this is really cool. So you, how many people are you like, coaching on leadership? And is this something you're doing all the time? Like is this like a you work with like one on one people? Are you just going over people's quiz like it's not a quiz? It's definitely a test. But like, are you are you going over these like individuals or with teams? How do you work with this?Kevin Kepple  That's a great question. So a few different ways, I do a little bit of one on one coaching, but not very scalable, because there's only one me. So I have actually some coaches that support the work that we do. So I have a good team underneath me that can extend out and do a little bit more one on one. But then I do a few different types of groups host a mastermind group for entrepreneurs and business owners that is really want to go further faster, you know, like minded people and like minded journeys, and I love that we're all co elevating together and also do some corporate work, I work with a couple of different CEOs, and then work with their leadership team as well. And just helping them really to, you know, be better, faster, smarter, and build a better, more powerful culture and really just lean into the gifts that God gave them to go out and create whatever their version of amazing is. And so long answer to a short question.Lesley Logan  No, but I find it fascinating cuz of course, my brain was like, well, do you like, do you make sure that there's a bunch of different strengths represented in your mastermind. Like my other and then another thought, because a bounce was like, are you ever do you ever do that with the CEO and their leadership team and realize, "Hey, you've got like these people doing like, the wrong roles." Do you ever like move people around so that they can be more aligned with their strengths or you kind of just help them find balconies in their roles with what they've got?Kevin Kepple  I mean, if they do internal shuffling, that's, you know, I don't really do the consulting piece as much as I have. But I really prefer just helping people figure out whatever it is that's, you know, stopping them slowing down standing in the way. Because it's like, when we're happier, we perform better period, right? (Lesley: Yeah) And we're all innately happy, we're just covered up with all this BS, it doesn't matter. And so a big part of what we do is know, like, limiting beliefs, right? So simple, but a lot of people just don't understand it. Even if they've heard the phrase, they don't, they don't know what's limiting them, right? And helping people learn to master the mindset and the heart set. Because so many people give away all that power, right? It's just the mindset, it's all they use, right? It's all logic and reason. I'm like, dude, your mind is a fraction of your being. Like, you don't have to use it all the time. Like when I sit down, I don't use my legs. Not much, right? I don't need to use my mind constantly. But if I'm trying to use reason and logic, where there's no risk and reason and logic, right, I'm eliminating all that. And I'm going to stick to the known and I'm going to crawl through life, like very slowly. But when I can go through the gut, right? That intuition, that knowingness, like, I know what's for me, like, I knew this podcast was for me. I knew the space was for me, right? And then I go into the heart, like, where's the energy? Where's the love? Like, dude, I love your attitude, your energy, the way that y'all do recaps. I'll heard y'all doing one. I was like, "Is that something they do all the time?" (Lesley: Oh, yeah.) Then the basement came out. And I'm like, "Hey wait, they're gonna do that about me." And I'm like, "Wait, that's awesome. I think it'd be really cool." And then like, go into the head for the planning, right? And then I did want to leverage that mind to create the plan. And then I use reason, then I use logic, right? Once I've already like, you know, gone through the, like, most infinite parts of me down here. And so if that makes sense ...Lesley Logan  Yeah, that's so far, there's, like, 17 things I wanted to touch on. But one of the things I love the beginning is you, you are not being everything in in that role, like, of course, you could probably consult for them, you can make it part of your package, but you are actually like, going, "This is what I actually do. This is what I really like to do. This is where I really excel and doing it." And this, and that's good. You know, I think a lot of times, I'm, as we coach people, they're like, "Well, I can do this, and I can do this, I'm gonna do all these things." And I'm like, "Okay, and you're gonna, that's exhausting. Do you really want to spend that much time with people do? Do you know how much time you just said, you're gonna make sure that person you're selling it to?" So I think that's because so because I think a lot of people would do that. So I love that you shared that because I hope it gives people listening permission to like, like, it's not limiting, because now you have like, it's like more energizing to do what you do by just giving yourself like, this is a thing I like to do.Kevin Kepple  Yeah, I mean, that's such a great point. You know energies, like, either there. It's not right. Like, we feel really good about things, or maybe they take our energy away. And that's a really cool thing again about this assessment. It just shows you your natural sources of energy. (Lesley: Yeah.) And you know, just like, "Hey, I've got this predisposition for doing this. So what does it look like when I invest time learn about it and actually using it?" And that's how your superpowers and it's so funny, like, I work with this tool, so many different amazing people and asked this question, probably 200 times, like, "Hey, tell me your top strengths." Like with somebody I've already worked with for a decent amount of time. They look at me, and I look at their phone, or they start going through their papers. Like waiting, waiting, and they finally fall, "Okay, oh my gosh, I can activate her and I got this. And I got that." I'm like, "Dude, do you think it would be awkward if we were walking down the street, we met Superman. And we asked him what his superpowers were. But he had to look at his iPhone and tell us he could fly like these are your superpowers? Don't you think you should just take the time to memorize them?" Like, and you know, like Kevin included because my coach will one point was like, "Hey, what are your strengths." And I pull it off the shelf? I'm like, blow the dust off.Lesley Logan  Yeah, I I love thinking of it like that. And I think I hope everyone listening goes and gives himself the test, if you haven't, or dusts off the strengths if you have and, and, and dive in and get to know yourself a little bit more. Because when we, the more we know about ourselves, the easier it is to, like, lean in and be ourselves and be that for others. And I think that's I mean, that's kind of how you be it till you see it.Kevin Kepple  Yeah, exactly. And know that so I read that in a good book once.Lesley Logan  All right, we're gonna take a quick break, and we're gonna find out how we can find out, how we can work with you more.So Kevin, where can people find you, follow you, share their superpowers with you?Kevin Kepple  @kevinkepple on Instagram or LinkedIn. Unlock Your Freedom Podcast with my name. Yeah, really any social media wherever you like to go. Yeah, just reach out if I can help and I love helping people. I've got a question. Let me know. If you're wanting to take the assessment by the way, it's kind of hard to find. We were talking about just Google Clifton Strengths Assessment purchase. That's what you put in like ... (Lesley: Put and purchase.) Yeah. It's gonna get you to the right place.Lesley Logan  We'll put the link below and if you don't know, everyone, it's really easy. You can just swipe on up and like my team puts all these links, including how to get to Kevin, how to get this podcast and all that. So but yeah, it's, it's also very interesting if you buy it for other people then you have to figure out how to find that purchase, but you can it's possible we we've done it. (Kevin: Yeah) So well have that their. So Kevin, we ask everybody be it till you see it. Bold, executable, intrinsic, targeted action steps people can take to be it till they see it.Kevin Kepple  Yeah, what a great question. I think like keeping it really simple, right? Leonardo da Vinci, simplicity is the ultimate sophistication. Like such good advice. So ask yourself two questions like, "What do I want? And why do I want it?" You know, what am I passionate about creating right now? What absolutely I love? And then why? How can I mix generosity into that? Because passion is a little selfish sometimes. And don't ask how. Because if you knew how you'd already be doing it, what do you want? Why do you want it? And you know, just without judgment, like what's slowing me down, what stand in the way was stopping me and find somebody powerful like Lesley pay her money so that she can help you go further faster, because you will always go faster with a really powerful coach. That is really really lethal, beautiful combination of a big heart and a big brain. And that's definitely what Lesley Logan is. And so I would highly suggest find somebody like her to take you wherever you want to go.Lesley Logan  Oh, my gosh, Kevin, well, like attracts like, so same to you. Thank you. These are great questions. Everyone, how are you gonna use these in your life? Let us know tag Kevin on Instagram, tag the @be_it_pod. Share this with a friend. Take your test, share your top five with us and your friends because the more we all know about ourselves, the easier it is to be it till you see it and if we're all doing this, I'm like, "What a better world we're all living in. So much easier." So thank you so much and until next time, Be It Till You See It.Transcribed by https://otter.aiSupport this podcast at — https://redcircle.com/be-it-till-you-see-it/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

From Season 1 of the Leadership Journey – “Win by Don't” Show Notes: This week on the Leadership Journey podcast, Keith and Brian get in-depth on behavior. Brian calls this “Win by Don't,” by painting a picture of how behavior is core to a program's success. He gives us the five “Don'ts” that are pivotal not only to football but life. The hosts give real-life examples of how this works and how they have been affected by different behavioral situations, emphasizing why it is important to have these instilled in your program if not already implementing them now. 02:14 Behavior runs everything 04:00 Influences of behavior 05:45 Grinder mentality 08:00 Culture and Strategy 09:25 Execution is the intersection of culture and strategy 10:00 Culture is to drive winning behavior 12:40 Simplify behavior 13:00 Behavior is 3 things 13:10 What you do 13:28 What you don't do 13:50 How do you do it 17:20 Win by don't 17:30 Success begins with the things you choose not to do 17:55 Don't do anything that can cost you everything 18:25 5 Don'ts 19:25 Don't do anything that can take away from practice or playing time 21:03 Do not lie 24:07 Don't BCD - blame, complain, or be defensive 25:15 Don't violate the culture 27:15 Don't get involved with the wrong people 30:00 You can do everything but those 5 31:30 Success begins with giving yourself a chance 33:00 All of it transfers 33:45 Make sure you're living what you promote

Brandon Napolean Brandon Napoleon was named to FootballScoop's 2022 Minority Watch List/Rising Stars in coaching. In 2022 he became Sacred Heart's cornerbacks coach after serving one year as a grad assistant at Buffalo. As a player, Napoleon spent two years at WVU before transferring to Northern Iowa. He also made a stop at Georgetown College, an NAIA school in Kentucky before finishing his collegiate career at Kansas Wesleyan.  On today's podcast e shares what he learned in his journey as a player and how that has transitioned into the coaching profession and developing the Cornerback position. Shownotes: -Path through college as a player -What he learned and message to players thinking about the transfer portal -Mindset - hard hat mentality -Keeping things interesting in the meeting room -Attention to detail with film and walk thru -Intensifying the walk thru -A-B-C-D in individual period -Coaching the toughest aspect of Corner play - eye discipline -Watching both corners in practice and game -Evaluation and playing time -Tracking player production -Defining a loaf -Progression of adjustments -The winning edge - the juice Related: Matt Myers - Head Coach, Kansas Wesleyan https://soundcloud.com/user-804678956/the-path-from-volunteer-to-head-coach-matt-myers-head-coach-kansas-wesleyan Matt Drinkall, TE Coach, Army https://soundcloud.com/user-804678956/sets/matt-drinkall-playlist Maurice Linguist, Head Coach, Buffalo https://soundcloud.com/user-804678956/how-we-teach-and-implement-maurice-lindquist-head-coach-university-of-buffalo Keelon Brookins, CB Coach, Kent State https://soundcloud.com/user-804678956/coach-the-cb-coach-em-hard-love-em-harder-keelon-brookins-cb-coach-kent-state Deliberate Practice - Juice https://soundcloud.com/user-804678956/deliberate-practice-juice